

Contents

Company information

Breakdown of capital	1
----------------------	---

Individual financial statements

Balance sheet - Assets	2
------------------------	---

Balance sheet - Liabilities	3
-----------------------------	---

Statement of income	4
---------------------	---

Statement of comprehensive income	5
-----------------------------------	---

Statement of cash flows (Indirect method)	6
---	---

Statement of changes in shareholders' equity

Statement of changes in shareholders' equity (DMPL) – 01/01/2022–12/31/2022	7
---	---

Statement of changes in shareholders' equity (DMPL) – 01/01/2021–12/31/2021	8
---	---

Statement of added value	9
--------------------------	---

Consolidated financial statements

Balance sheet - Assets	10
------------------------	----

Balance sheet - Liabilities	11
-----------------------------	----

Statement of income	12
---------------------	----

Statement of comprehensive income	13
-----------------------------------	----

Statement of cash flows (Indirect method)	14
---	----

Statement of changes in shareholders' equity

Statement of changes in shareholders' equity (DMPL) – 01/01/2022–12/31/2022	15
---	----

Statement of changes in shareholders' equity (DMPL) – 01/01/2021–12/31/2021	16
---	----

Statement of added value	17
--------------------------	----

Management report/Comment on performance	18
--	----

Notes to the financial statements	21
-----------------------------------	----

Other information the Company deems to be relevant	71
--	----

Opinions and Statements

Independent Auditor's Report - Unqualified	74
--	----

Tax Council opinion or equivalent body	79
--	----

Summarized Report of the Audit Committee (statutory, provided for in specific CVM regulation)	80
---	----

Statement of the Executive Officers on the Financial Statements	81
---	----

Statement of the Executive Officers on Independent Auditor's Report	82
---	----

Company information / Breakdown of Capital

Quantity of shares (Unit)	Last fiscal year 12/31/2022
Paid-in capital	
Common	568,465,803
Preferred	0
Total	568,465,803
Treasury	
Common	15,970,140
Preferred	0
Total	15,970,140

Balance sheet - Assets - Individual

Amounts in thousands of reais (R\$)

Code of account	Account description	Current quarter 12/31/2022	Prior year 12/31/2021
1	Total assets	1,970,289	1,860,898
1.01	Current assets	424,473	515,928
1.01.01	Cash and cash equivalents	14,815	15,584
1.01.02	Interest earning bank deposits	184,123	289,303
1.01.02.01	Interest earning bank deposits valued at fair value through profit or loss	104,614	289,303
1.01.02.01.04	Free investments	104,614	289,303
1.01.02.03	Interest earning bank deposits valued at amortized cost	79,509	-
1.01.02.03.01	Investments that guarantee technical reserves	4,952	-
1.01.02.03.02	Free investments	74,557	-
1.01.03	Accounts receivable	185,349	164,971
1.01.03.01	Clients	171,283	145,331
1.01.03.01.01	Cash considerations/Premiums receivable	184,042	160,514
1.01.03.01.02	Provision for credit losses	(23,466)	(24,449)
1.01.03.01.03	Participation of beneficiaries in indemnifying events/claims	1,313	811
1.01.03.01.05	Healthcare plan operators	9,394	8,455
1.01.03.02	Other accounts receivable	14,066	19,640
1.01.03.02.01	Advances to suppliers and others	1,608	4,992
1.01.03.02.02	Advances to employees	7,471	6,608
1.01.03.02.03	Other Credits Receivable	4,987	8,040
1.01.06	Recoverable taxes	1,610	11,250
1.01.06.01	Current recoverable taxes	1,610	11,250
1.01.06.01.01	Tax and social security credits	1,610	11,250
1.01.07	Prepaid expenses	38,576	34,820
1.01.07.01	Deferred sales expenses	34,418	30,292
1.01.07.20	Other	4,158	4,528
1.02	Non-current assets	1,545,816	1,344,970
1.02.01	Long-term assets	629,931	460,244
1.02.01.03	Interest earning bank deposits valued at amortized cost	564,293	399,487
1.02.01.03.01	Investments that guarantee technical reserves	191,042	179,270
1.02.01.03.02	Free investments	373,251	220,217
1.02.01.07	Deferred taxes	6,031	24,762
1.02.01.07.01	Deferred income tax and social contribution	6,031	24,762
1.02.01.10	Other non-current assets	59,607	35,995
1.02.01.10.03	Judicial and tax deposits	24,237	22,027
1.02.01.10.04	Other credits receivable	18,423	13,889
1.02.01.10.05	Securities and credits receivable	-	79
1.02.01.10.06	Tax and social security credits (recoverable taxes)	16,947	-
1.02.02	Investments	77,285	60,279
1.02.02.01	Ownership interest	77,285	60,279
1.02.02.01.02	Interest in subsidiaries	70,124	54,916
1.02.02.01.03	Joint ownership	7,161	5,363
1.02.03	Property, plant and equipment	27,554	50,091
1.02.03.01	Construction in progress	14,788	18,675
1.02.03.01.01	Property, plant and equipment for use	9,045	12,165
1.02.03.01.02	Other property, plant and equipment	5,743	6,510
1.02.03.02	Right-of-use in leases	12,766	31,416
1.02.03.02.01	Right-of-use (CPC 06 (R2))/IFRS 16)	12,766	31,416
1.02.04	Intangible assets	811,046	774,356
1.02.04.01	Intangible assets	811,046	774,356
1.02.04.01.02	Goodwill in investment acquisitions	654,948	654,948
1.02.04.01.03	Development of systems and software use licenses	125,145	85,916
1.02.04.01.05	Allocated intangible assets	30,953	33,492

Balance sheet - Liabilities - Individual

Amounts in thousands of reais (R\$)

Code of account	Account description	Current quarter 12/31/2022	Prior year 12/31/2021
2	Total liabilities	1,970,289	1,860,898
2.01	Current liabilities	677,457	551,084
2.01.01	Social and labor obligations	52,842	44,387
2.01.01.01	Social charges	5,546	5,394
2.01.01.01.01	Charges payable	5,546	5,394
2.01.01.02	Labor obligations	47,296	38,993
2.01.01.02.01	Salaries, vacation and fees	47,296	38,993
2.01.02	Suppliers	18,341	19,801
2.01.02.01	Domestic suppliers	18,341	19,801
2.01.02.01.01	Trading on operations	5,466	448
2.01.02.01.02	Suppliers of assets and services	11,755	16,607
2.01.02.01.04	Consideration/premiums to be repaid	40	179
2.01.02.01.05	Lease liabilities (CPC 06 (R2)/IFRS 16)	2,059	4,785
2.01.02.01.06	Present value adjustment (PVA) - lease liability (CPC 06 (R2)/IFRS 16)	(979)	(2,218)
2.01.03	Tax liabilities	32,489	22,897
2.01.03.01	Federal tax liabilities	22,861	13,540
2.01.03.01.01	Income tax and social contribution payable	8,458	1,018
2.01.03.01.02	Other federal tax liabilities	14,403	12,522
2.01.03.03	Municipal tax liabilities	9,628	9,357
2.01.05	Other liabilities	173,602	109,382
2.01.05.02	Other	173,602	109,382
2.01.05.02.01	Dividends and interest on own capital payable	7	20
2.01.05.02.02	Minimum mandatory dividend payable	95,913	40,520
2.01.05.02.06	Repurchase of shares payable	-	7,044
2.01.05.02.04	Advances from clients	527	-
2.01.05.02.05	Other accounts payable	57,362	49,571
2.01.05.02.08	Investments payable	15,968	8,637
2.01.05.02.09	Contingent considerations	3,825	3,590
2.01.06	Provisions	400,183	354,617
2.01.06.02	Other provisions	400,183	354,617
2.01.06.02.04	Provision for Unsettled claims (UC)	68,197	54,969
2.01.06.02.05	Provision for Events/Incurred claims but Not Reported (PEONA)	101,116	98,534
2.01.06.02.06	Provision for unearned premiums (UP)/considerations	230,870	201,114
2.02	Non-current liabilities	108,673	194,010
2.02.02	Other liabilities	56,081	113,364
2.02.02.02	Other	56,081	113,364
2.02.02.02.03	Other liabilities	18,957	13,648
2.02.02.02.04	Fees payable	489	1,068
2.02.02.02.05	Put option in Subsidiary	-	39,894
2.02.02.02.06	Investments payable	4,751	13,121
2.02.02.02.07	Lease liabilities (CPC 06 (R2)/IFRS 16)	17,753	37,852
2.02.02.02.08	Present value adjustment (PVA) - lease liability (CPC 06 (R2)/IFRS 16)	(3,743)	(7,451)
2.02.02.02.09	Long-term incentive (ILP)	17,874	11,823
2.02.02.02.10	Contingent considerations	-	3,409
2.02.04	Provisions	52,592	80,646
2.02.04.01	Tax, social security, labor and civil provisions	34,037	64,792
2.02.04.01.01	Tax provisions	1,455	42,957
2.02.04.01.02	Social security and labor provisions	1,369	2,020
2.02.04.01.04	Civil provisions	31,213	19,815
2.02.04.02	Other provisions	18,555	15,854
2.02.04.02.04	Installment payments of taxes and contributions	894	1,515
2.02.04.02.05	Taxes and charges payable	17,661	14,339
2.03	Shareholders' equity	1,184,159	1,115,804
2.03.01	Realized capital	851,017	851,017
2.03.02	Capital reserves	(36,979)	(61,223)
2.03.02.04	Options granted	-	2,845
2.03.02.08	Additional paid-up capital	-	(22,881)
2.03.02.09	Put option in Subsidiary	(987)	(41,187)
2.03.02.10	Goodwill/negative goodwill in capital transaction	(35,992)	-
2.03.04	Profit reserves	369,981	326,010
2.03.04.01	Legal reserve	73,921	51,313
2.03.04.07	Tax incentive reserve	129	129
2.03.04.08	Additional dividend proposed	24,087	-
2.03.04.09	Treasury shares	(163,046)	(189,805)
2.03.04.10	Statutory Reserve of Regulatory Capital	174,568	243,147
2.03.04.11	Investment and expansion reserve	260,322	221,226
2.03.06	Equity valuation adjustments	140	-

Statement of income (DR) - Individual

Amounts in thousands of reais (R\$)

Code of account	Account description	Current Year-to-date 01/01/2022-12/31/2022	Accumulated of the prior year 01/01/2021-12/31/2021
3.01	Revenue from sales of goods and/or services	1,876,738	1,809,030
3.01.01	Net considerations/Retained premiums	1,967,571	1,891,478
3.01.04	Direct taxes from operations with health care plans for the operator	(90,833)	(82,448)
3.02	Cost of goods and/or services sold	(726,411)	(724,652)
3.02.01	Known or reported events/claims	(687,436)	(695,884)
3.02.03	Dental materials	(12,466)	(14,253)
3.02.04	Other operating costs	(24,167)	(7,567)
3.02.05	Changes in provision for events/claims incurred but Not Reported (PEONA)	(2,342)	(6,948)
3.03	Gross Income	1,150,327	1,084,378
3.04	Operating expenses/revenues	(584,228)	(580,507)
3.04.01	Sales expenses	(210,137)	(188,791)
3.04.01.01	Sales expenses	(210,137)	(188,791)
3.04.02	Administrative and general expenses	(306,716)	(320,990)
3.04.02.01	Administrative expenses	(297,596)	(316,193)
3.04.02.02	Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	(2,557)	(3,788)
3.04.02.03	Rentals	(2,467)	(4,675)
3.04.02.04	Rents (CPC 06 (R2)/IFRS 16)	2,386	4,772
3.04.02.05	Income (loss) from disposal or write-off of non-current asset items and other	(6,482)	(1,106)
3.04.04	Other operating revenues	1,441	1,808
3.04.04.01	Other operating revenues from Healthcare plans	973	398
3.04.04.02	Revenues from health care plans for the Operator	468	1,410
3.04.05	Other operating expenses	(91,163)	(84,767)
3.04.05.02	Provision for credit losses	(47,477)	-48,663
3.04.05.03	Profit sharing	(23,605)	(20,037)
3.04.05.04	Long-term incentive program (ILP)	(20,081)	(16,067)
3.04.06	Equity in net income of subsidiaries	22,347	12,233
3.05	Income (loss) before financial income (loss) and taxes	566,099	503,871
3.06	Financial income (loss)	70,488	39,528
3.06.01	Financial revenues	85,116	52,687
3.06.01.01	Financial revenues	85,116	52,687
3.06.02	Financial expenses	(14,628)	(13,159)
3.06.02.01	Financial expenses	(83,284)	(63,195)
3.06.02.02	Present value adjustment (PVA) - lease liability (CPC 06 (R2)/IFRS 16)	(601)	(2,196)
3.06.02.03	Reversal of interest on own capital (JCP)	69,257	52,232
3.07	Income (loss) before income taxes	636,587	543,399
3.08	Income tax and social contribution on income	(184,416)	(163,040)
3.08.01	Current	(165,685)	(154,865)
3.08.02	Deferred	(18,731)	(8,175)
3.09	Net income (loss) of continued operations	452,171	380,359
3.11	Income (loss) for the year	452,171	380,359
3.99	Earnings per share - (Reais R\$ / Shares)		
3.99.01	Basic earnings per share		
3.99.01.01	Common shares	0.81779	0.72217
3.99.02	Diluted earning per share		
3.99.02.01	Common shares	0.81779	0.72128

Statement of comprehensive income - Individual

Amounts in thousands of reais (R\$)

Code of account	Account description	Current quarter 10/01/2022-12/31/2022	Current Year-to-date 01/01/2022-12/31/2022	Current quarter 10/01/2021-12/31/2021	Accumulated of the prior year 01/01/2021-12/31/2021
4.01	Consolidated net income for the period	94,951	452,171	87,179	380,359
4.02	Other comprehensive income	(265)	140	-	-
4.02.01	Accumulated translation adjustment	206	607	-	-
4.02.02	Other	(471)	(467)	-	-
4.03	Comprehensive income for the period	94,686	452,311	87,179	380,359

Statements of cash flows – Indirect method - Individual

Amounts in thousands of reais (R\$)

Account	Description	Current Year-to-date 01/01/2022–12/31/2022	Accumulated of the prior year 01/01/2021–12/31/2021
6.01	Net cash from operating activities	687,539	851,880
6.01.01	Cash generated in operations	754,327	689,777
6.01.01.01	Net income (loss) for the period	452,171	380,359
6.01.01.02	Depreciation and amortization	29,781	55,433
6.01.01.03	Net inflation adjustments	7,230	2,643
6.01.01.05	Provisions for lawsuits (Contingencies)	16,247	22,824
6.01.01.06	Income (loss) from disposal of non-current assets and other	6,482	1,106
6.01.01.07	Equity in net income of subsidiaries	(22,347)	(12,233)
6.01.01.08	Provision for credit losses	47,477	48,663
6.01.01.10	Changes in provision for events/claims incurred but Not Reported (PEONA)	2,342	6,948
6.01.01.11	Provision for income tax and social contribution	184,416	163,040
6.01.01.12	Provision for unearned premiums (UP)/considerations	29,756	19,782
6.01.01.13	Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	2,557	3,788
6.01.01.14	Rents (CPC 06 (R2)/IFRS 16)	(2,386)	(4,772)
6.01.01.15	Present value adjustment (PVA) - lease liability (CPC 06 (R2)/IFRS 16)	601	2,196
6.01.02	Changes in assets and liabilities	(66,788)	162,103
6.01.02.01	Interest earning bank deposits (Financial assets at fair value through profit or loss)	184,689	392,962
6.01.02.02	Receivables from operations with healthcare plans (clients)	(73,429)	(61,140)
6.01.02.03	Other accounts receivable, recoverable taxes and prepaid expenses	11,458	14,318
6.01.02.05	Long-term assets (Non current)	(20,635)	(3,354)
6.01.02.06	Provision for Unsettled claims (UC)	13,228	(16,179)
6.01.02.09	Tax obligations (taxes payable)	(8,237)	164
6.01.02.10	Labor obligations, Suppliers, Advance from clients and Other accounts payable (Sundry debits)	22,597	1,928
6.01.02.11	Non-current liabilities	(43,384)	(2,665)
6.01.02.13	Income tax and social contribution paid	(158,245)	(163,980)
6.01.02.14	Social charges (Charges payable)	152	2,220
6.01.02.15	Trading on operations	5,018	(2,171)
6.02	Net cash from investment activities	(348,493)	(439,766)
6.02.01	Acquisitions of property, plant and equipment	(6,799)	(5,055)
6.02.02	Development of systems and software use licenses	(62,637)	(46,031)
6.02.05	Write-off of investments due to merger	4,483	4,470
6.02.06	Acquisition of investment	(44,394)	(15,730)
6.02.07	Dividends received from Subsidiaries and jointly-controlled subsidiaries	5,169	5,526
6.02.11	Interest earning bank deposits (Financial assets valued at amortized cost)	(244,315)	(382,946)
6.03	Net cash from financing activities	(339,815)	(429,976)
6.03.01	Dividends and interest on own capital paid	(169,777)	(261,159)
6.03.02	Acquisition of own shares - Treasury	(170,090)	(170,005)
6.03.04	Receipt of granting stock option	52	1,188
6.05	Increase (decrease) in cash and cash equivalents	(769)	(17,862)
6.05.01	Opening balance of cash and cash equivalents	15,584	33,446
6.05.02	Closing balance of cash and cash equivalents	14,815	15,584

Statements of changes in shareholders' equity/DMPL – 01/01/2022–12/31/2022 - Individual

Amounts in thousands of reais (R\$)

Account	Description	Paid-up capital	Capital reserves, options granted and treasury shares	Profit reserves	Retained earnings or losses	Other comprehensive income	Shareholders' equity
5.01	Opening balances	851,017	(251,028)	515,815	-	-	1,115,804
5.03	Adjusted opening balances	851,017	(251,028)	515,815	-	-	1,115,804
5.04	Capital transactions with partners	-	51,003	(185,702)	(249,257)	-	(383,956)
5.04.04	Treasury shares acquired	-	(163,046)	-	-	-	(163,046)
5.04.05	Treasury shares sold	-	52	-	-	-	52
5.04.06	Dividends	-	-	-	(60,000)	-	(60,000)
5.04.07	Interest on own capital	-	-	-	(69,257)	-	(69,257)
5.04.08	Goodwill/negative goodwill in capital transaction	-	(35,992)	-	-	-	(35,992)
5.04.09	Absorption of reserve for granting stock option	-	19,984	(19,984)	-	-	-
5.04.17	Additional dividend proposed	-	-	-	(95,913)	-	(95,913)
5.04.18	Additional dividend proposed	-	-	24,087	(24,087)	-	-
5.04.19	Put option in Subsidiary	-	40,200	-	-	-	40,200
5.04.20	Cancellation of treasury shares	-	189,805	(189,805)	-	-	-
5.05	Total comprehensive income	-	-	-	452,171	-	452,171
5.05.01	Net income for the period	-	-	-	452,171	-	452,171
5.05.02	Other comprehensive income	-	-	-	-	140	140
5.05.02.04	Translation adjustments in the period	-	-	-	-	140	140
5.06	Internal changes in shareholders' equity	-	-	202,914	(202,914)	-	-
5.06.01	Formation of reserves	-	-	202,914	(202,914)	-	-
5.07	Closing balances	851,017	(200,025)	533,027	-	140	1,184,159

Statements of changes in shareholders' equity/DMPL – 01/01/2021–12/31/2021 - Individual

Amounts in thousands of reais (R\$)

Account	Description	Paid-up capital	Capital reserves, options granted and treasury shares	Profit reserves	Retained earnings or losses	Shareholders' equity
5.01	Opening balances	607,869	(25,021)	619,431	-	1,202,279
5.03	Adjusted opening balances	607,869	(25,021)	619,431	-	1,202,279
5.04	Capital transactions with partners	243,148	(226,007)	(295,469)	(188,506)	(466,834)
5.04.01	Capital increases	243,148	(48,392)	(194,756)	-	-
5.04.04	Treasury shares acquired	-	(177,049)	-	-	(177,049)
5.04.05	Treasury shares sold	-	1,188	-	-	1,188
5.04.06	Dividends	-	-	-	(95,754)	(95,754)
5.04.07	Interest on own capital	-	-	-	(52,232)	(52,232)
5.04.10	Additional dividend paid	-	-	-	(40,520)	(40,520)
5.04.17	Additional dividend proposed	-	-	-	-	-
5.04.19	Put option in Subsidiary	-	(1,754)	-	-	(1,754)
5.05	Total comprehensive income	-	-	-	380,359	380,359
5.05.01	Net income for the period	-	-	-	380,359	380,359
5.06	Internal changes in shareholders' equity	-	-	191,853	(191,853)	-
5.06.01	Formation of reserves	-	-	191,853	(191,853)	-
5.07	Closing balances	851,017	(251,028)	515,815	-	1,115,804

Statement of added value - Individual

Amounts in thousands of reais (R\$)

Account	Description	Current Year-to-date 01/01/2022–12/31/2022	Accumulated of the prior year 01/01/2021–12/31/2021
7.01	Revenues	1,920,094	1,842,815
7.01.01	Sale of goods, products and services	1,967,571	1,891,478
7.01.04	Formation/reversal of allowance for doubtful accounts	(47,477)	(48,663)
7.02	Inputs acquired from third parties	(1,116,459)	(1,055,442)
7.02.01	Cost of products, goods and services sold	(687,436)	(695,884)
7.02.02	Materials, energy, outsourced services and other	(15,607)	(17,682)
7.02.04	Other	(413,416)	(341,876)
7.02.04.01	Other operating revenues (expenses)	(19,418)	(2,463)
7.02.04.02	Sales expenses	(208,847)	(187,731)
7.02.04.03	Administrative expenses	(182,809)	(144,734)
7.02.04.04	Changes in provision for events/claims incurred but Not Reported (PEONA)	(2,342)	(6,948)
7.03	Gross added value	803,635	787,373
7.04	Retentions	(32,338)	(59,221)
7.04.01	Depreciation, amortization and depletion	(29,781)	(55,433)
7.04.02	Other	(2,557)	(3,788)
7.04.02.01	Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	(2,557)	(3,788)
7.05	Net added value produced	771,297	728,152
7.06	Added value received as transfer	107,463	64,920
7.06.01	Equity in net income of subsidiaries	22,347	12,233
7.06.02	Financial revenues	85,116	52,687
7.07	Total added value payable	878,760	793,072
7.08	Distribution of added value	878,760	793,072
7.08.01	Personnel	141,877	121,610
7.08.01.01	Direct remuneration	117,283	97,511
7.08.01.02	Benefits	19,641	18,875
7.08.01.03	Severance Pay Fund (FGTS)	4,953	5,224
7.08.02	Taxes, duties and contributions	270,003	278,041
7.08.02.01	Federal	239,047	250,310
7.08.02.02	State	69	51
7.08.02.03	Municipal	30,887	27,680
7.08.03	Third-party capital remuneration	14,709	13,062
7.08.03.02	Rentals	81	(97)
7.08.03.03	Other	14,628	13,159
7.08.03.03.01	Financial expenses	14,628	13,159
7.08.04	Remuneration of own capital	452,171	380,359
7.08.04.01	Interest on own capital	69,257	52,232
7.08.04.02	Dividends	180,000	136,274
7.08.04.03	Retained earnings/losses for the year	202,914	191,853

Balance sheet - Assets - Consolidated

Amounts in thousands of reais (R\$)

Account	Description	Current quarter 12/31/2022	Prior year 12/31/2021
1	Total assets	2,019,853	1,933,841
1.01	Current assets	498,898	582,488
1.01.01	Cash and cash equivalents	15,837	16,422
1.01.02	Interest earning bank deposits	215,101	315,140
1.01.02.01	Interest earning bank deposits valued at fair value through profit or loss	135,592	315,140
1.01.02.01.03	Investments that guarantee technical reserves	-	882
1.01.02.01.04	Free investments	135,592	314,258
1.01.02.03	Interest earning bank deposits valued at amortized cost	79,509	-
1.01.02.03.01	Investments that guarantee technical reserves	4,952	-
1.01.02.03.02	Free investments	74,557	-
1.01.03	Accounts receivable	214,866	191,074
1.01.03.01	Clients	174,567	157,193
1.01.03.01.01	Cash considerations/Premiums receivable	178,261	161,420
1.01.03.01.02	Provision for credit losses	(23,253)	(24,800)
1.01.03.01.03	Participation of beneficiaries in indemnifying events/claims	1,313	811
1.01.03.01.05	Healthcare plan operators	5,191	8,455
1.01.03.01.06	Other receivables from operations with healthcare plans	13,055	11,307
1.01.03.02	Other accounts receivable	40,299	33,881
1.01.03.02.01	Advances to suppliers and others	5,503	9,051
1.01.03.02.02	Advances to employees	9,557	7,126
1.01.03.02.03	Other Credits Receivable	25,239	17,704
1.01.04	Inventories	4,767	4,421
1.01.06	Recoverable taxes	8,968	19,912
1.01.06.01	Current recoverable taxes	8,968	19,912
1.01.06.01.01	Tax and social security credits	8,968	19,912
1.01.07	Prepaid expenses	39,359	35,519
1.01.07.01	Deferred sales expenses	34,418	30,292
1.01.07.20	Other	4,941	5,227
1.02	Non-current assets	1,520,955	1,351,353
1.02.01	Long-term assets	635,719	480,326
1.02.01.03	Interest earning bank deposits valued at amortized cost	564,293	399,487
1.02.01.03.01	Investments that guarantee technical reserves	191,042	179,270
1.02.01.03.02	Free investments	373,251	220,217
1.02.01.07	Deferred taxes	9,213	28,097
1.02.01.07.01	Deferred income tax and social contribution	9,213	28,097
1.02.01.10	Other non-current assets	62,213	52,742
1.02.01.10.03	Judicial and tax deposits	26,559	25,366
1.02.01.10.04	Other credits receivable	18,707	27,297
1.02.01.10.05	Securities and credits receivable	-	79
1.02.01.10.06	Tax and social security credits (recoverable taxes)	16,947	-
1.02.02	Investments	17,860	14,493
1.02.02.01	Ownership interest	17,860	14,493
1.02.02.01.02	Interests in other companies	1,795	1,289
1.02.02.01.03	Joint ownership	16,065	13,204
1.02.03	Property, plant and equipment	44,743	70,235
1.02.03.01	Construction in progress	25,002	29,517
1.02.03.01.01	Property, plant and equipment for use	17,890	21,895
1.02.03.01.02	Other property, plant and equipment	7,112	7,622
1.02.03.02	Right-of-use in leases	19,741	40,718
1.02.03.02.01	Right-of-use (CPC 06 (R2))/IFRS 16)	19,741	40,718
1.02.04	Intangible assets	822,633	786,299
1.02.04.01	Intangible assets	822,633	786,299
1.02.04.01.02	Goodwill in investment acquisitions	663,990	663,990
1.02.04.01.03	Development of systems and software use licenses	127,279	88,356
1.02.04.01.05	Allocated intangible assets	31,364	33,953

Balance sheet - Liabilities - Consolidated

Amounts in thousands of reais (R\$)

Account	Description	Current quarter 12/31/2022	Prior year 12/31/2021
2	Total liabilities	2,019,853	1,933,841
2.01	Current liabilities	717,704	591,361
2.01.01	Social and labor obligations	63,977	56,508
2.01.01.01	Social charges	7,538	7,820
2.01.01.01.01	Charges payable	7,538	7,820
2.01.01.02	Labor obligations	56,439	48,688
2.01.01.02.01	Salaries, vacation and fees	56,439	48,688
2.01.02	Suppliers	27,834	26,222
2.01.02.01	Domestic suppliers	27,834	26,222
2.01.02.01.01	Trading on operations	6,366	1,062
2.01.02.01.02	Suppliers of assets and services	19,102	20,910
2.01.02.01.04	Consideration/premiums to be repaid	40	179
2.01.02.01.05	Lease liabilities (CPC 06 (R2)/IFRS 16)	3,659	6,943
2.01.02.01.06	Present value adjustment (PVA) - lease liability (CPC 06 (R2)/IFRS 16)	(1,333)	(2,872)
2.01.03	Tax liabilities	35,792	26,579
2.01.03.01	Federal tax liabilities	25,869	16,834
2.01.03.01.01	Income tax and social contribution payable	8,944	1,468
2.01.03.01.02	Other federal tax liabilities	16,925	15,366
2.01.03.02	State tax liabilities	105	61
2.01.03.03	Municipal tax liabilities	9,818	9,684
2.01.05	Other liabilities	182,512	116,081
2.01.05.02	Other	182,512	116,081
2.01.05.02.01	Dividends and interest on own capital payable	7	20
2.01.05.02.02	Minimum mandatory dividend payable	95,913	40,520
2.01.05.02.04	Advances from clients	634	1,703
2.01.05.02.05	Other accounts payable	66,165	54,567
2.01.05.02.06	Repurchase of shares payable	-	7,044
2.01.05.02.08	Investments payable	15,968	8,637
2.01.05.02.09	Contingent considerations	3,825	3,590
2.01.06	Provisions	407,589	365,971
2.01.06.02	Other provisions	407,589	365,971
2.01.06.02.04	Provision for Unsettled claims (UC)	63,230	55,427
2.01.06.02.05	Provision for Events/Incurred claims but Not Reported (PEONA)	101,116	98,774
2.01.06.02.06	Provision for unearned premiums (UP)/considerations	230,870	201,370
2.01.06.02.07	Other technical reserves (OTHER)	12,373	10,400
2.02	Non-current liabilities	116,631	221,231
2.02.02	Other liabilities	62,672	137,520
2.02.02.02	Other	62,672	137,520
2.02.02.02.03	Other liabilities	18,957	26,762
2.02.02.02.04	Fees payable	489	1,068
2.02.02.02.05	Put option in Subsidiary	987	41,187
2.02.02.02.06	Investments payable	4,759	13,130
2.02.02.02.07	Lease liabilities (CPC 06 (R2)/IFRS 16)	22,679	48,100
2.02.02.02.08	Present value adjustment (PVA) - lease liability (CPC 06 (R2)/IFRS 16)	(4,584)	(9,406)
2.02.02.02.09	Long-term incentive (ILP)	19,385	13,270
2.02.02.02.10	Contingent considerations	-	3,409
2.02.04	Provisions	53,959	83,711
2.02.04.01	Tax, social security, labor and civil provisions	35,404	67,857
2.02.04.01.01	Tax provisions	2,613	45,624
2.02.04.01.02	Social security and labor provisions	1,578	2,418
2.02.04.01.04	Civil provisions	31,213	19,815
2.02.04.02	Other provisions	18,555	15,854
2.02.04.02.04	Installment payments of taxes and contributions	894	1,515
2.02.04.02.05	Taxes and charges payable	17,661	14,339
2.03	Shareholders' equity	1,185,518	1,121,249
2.03.01	Realized capital	851,017	851,017
2.03.02	Capital reserves	(36,979)	(61,223)
2.03.02.04	Options granted	-	2,845
2.03.02.08	Additional paid-up capital	-	(22,881)
2.03.02.09	Put option in Subsidiary	(987)	(41,187)
2.03.02.10	Goodwill/negative goodwill in capital transaction	(35,992)	-
2.03.04	Profit reserves	369,981	326,010
2.03.04.01	Legal reserve	73,921	51,313
2.03.04.07	Tax incentive reserve	129	129
2.03.04.08	Additional dividend proposed	24,087	-
2.03.04.09	Treasury shares	(163,046)	(189,805)
2.03.04.10	Statutory Reserve of Regulatory Capital	174,568	243,147
2.03.04.11	Investment and expansion reserve	260,322	221,226
2.03.06	Equity valuation adjustments	140	-
2.03.09	Non-controlling interest	1,359	5,445

Statement of income (DR) - Consolidated

Amounts in thousands of reais (R\$)

Code of account	Account description	Current Year-to-date 01/01/2022–12/31/2022	Accumulated of the prior year 01/01/2021–12/31/2021
3.01	Revenue from sales of goods and/or services	1,902,422	1,842,434
3.01.01	Net considerations/Retained premiums	1,967,497	1,898,595
3.01.02	Sales of goods and services	21,892	16,406
3.01.04	Direct taxes from operations with health care plans for the operator	(90,833)	(82,827)
3.01.05	Taxes on sales of goods and services	(14,813)	(14,247)
3.01.06	Insurance	18,679	24,507
3.02	Cost of goods and/or services sold	(732,443)	(731,477)
3.02.01	Known or reported events/claims	(675,268)	(688,291)
3.02.02	Payroll charges on services	-	(98)
3.02.03	Dental materials	(6,349)	(8,805)
3.02.04	Other operating costs	(42,695)	(22,194)
3.02.05	Changes in provision for events/claims incurred but Not Reported (PEONA)	(2,342)	(6,921)
3.02.06	Claims	(5,769)	(4,926)
3.02.07	Claims technical Reserves	(20)	(242)
3.03	Gross Income	1,169,979	1,110,957
3.04	Operating expenses/revenues	(596,388)	(603,005)
3.04.01	Sales expenses	(212,092)	(191,096)
3.04.01.01	Sales expenses	(212,092)	(191,096)
3.04.02	Administrative and general expenses	(298,406)	(332,384)
3.04.02.01	Administrative expenses	(286,567)	(325,459)
3.04.02.02	Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	(4,628)	(5,822)
3.04.02.03	Rentals	(5,596)	(7,213)
3.04.02.04	Rents (CPC 06 (R2)/IFRS 16)	5,027	7,234
3.04.02.05	Income (loss) from disposal or write-off of non-current asset items and other	(6,642)	(1,124)
3.04.04	Other operating revenues	2,635	4,302
3.04.04.01	Other operating revenues from Healthcare plans	2,167	2,792
3.04.04.02	Revenues from health care plans for the Operator	468	1,510
3.04.05	Other operating expenses	(95,134)	(90,386)
3.04.05.02	Provision for credit losses	(47,951)	(48,920)
3.04.05.03	Profit sharing	(26,106)	(24,082)
3.04.05.04	Long-term incentive program (ILP)	(21,077)	(17,384)
3.04.06	Equity in net income of subsidiaries	6,609	6,559
3.05	Income (loss) before financial income (loss) and taxes	573,591	507,952
3.06	Financial income (loss)	72,667	39,226
3.06.01	Financial revenues	88,843	54,283
3.06.01.01	Financial revenues	88,843	54,283
3.06.02	Financial expenses	(16,176)	(15,057)
3.06.02.01	Financial expenses	(84,111)	(64,306)
3.06.02.02	Present value adjustment (PVA) - lease liability (CPC 06 (R2)/IFRS 16)	(1,322)	(2,983)
3.06.02.03	Reversal of interest on own capital (JCP)	69,257	52,232
3.07	Income (loss) before income taxes	646,258	547,178
3.08	Income tax and social contribution on income	(194,897)	(165,838)
3.08.01	Current	(176,014)	(158,274)
3.08.02	Deferred	(18,883)	(7,564)
3.09	Net income (loss) of continued operations	451,361	381,340
3.11	Consolidated income/loss for the period	451,361	381,340
3.11.01	Attributed to the Parent company's partners	452,171	380,359
3.11.02	Attributed to non-controlling partners	(810)	981
3.99	Earnings per share - (Reais R\$ / Shares)		
3.99.01	Basic earnings per share		
3.99.01.01	Common shares	0.81779	0.72217
3.99.02	Diluted earning per share		
3.99.02.01	Common shares	0.81779	0.72128

Statement of comprehensive income - Consolidated

Amounts in thousands of reais (R\$)

Code of account	Account description	Current quarter 10/01/2022–12/31/2022	Current Year-to-date 01/01/2022–12/31/2022	Current quarter 10/01/2021–12/31/2021	Accumulated of the prior year 01/01/2021–12/31/2021
4.01	Consolidated net income for the period	94,991	451,361	86,733	381,340
4.02	Other comprehensive income	(265)	140	(374)	(724)
4.02.01	Accumulated translation adjustment	206	607	(374)	(724)
4.02.01	Other	(471)	(467)	-	-
4.03	Consolidated comprehensive income for the period	94,726	451,501	86,359	380,616
4.03.01	Attributed to the Parent company's partners	94,686	452,311	86,805	379,635
4.03.02	Attributed to non-controlling partners	40	(810)	(446)	981

Statements of cash flows – Indirect method - Consolidated

Amounts in thousands of reais (R\$)

Code of account	Account description	Current Year-to-date 01/01/2022–12/31/2022	Accumulated of the prior year 01/01/2021–12/31/2021
6.01	Net cash from operating activities	694,581	858,423
6.01.01	Cash generated in operations	782,791	704,942
6.01.01.01	Net income (loss) for the period	451,361	381,340
6.01.01.02	Depreciation and amortization	32,395	57,760
6.01.01.03	Net inflation adjustments	7,318	2,850
6.01.01.05	Provisions for lawsuits (Contingencies)	16,439	22,791
6.01.01.06	Income (loss) from disposal of non-current assets and other	6,642	1,124
6.01.01.07	Equity in net income of subsidiaries	(6,609)	(6,559)
6.01.01.08	Provision for credit losses	47,951	48,920
6.01.01.10	Changes in provision for events/claims incurred but Not Reported (PEONA)	2,342	6,921
6.01.01.11	Provision for income tax and social contribution	194,897	165,838
6.01.01.12	Provision for unearned premiums (UP)/considerations	29,500	19,981
6.01.01.13	Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	4,628	5,822
6.01.01.14	Rents (CPC 06 (R2)/IFRS 16)	(5,027)	(7,234)
6.01.01.15	Present value adjustment (PVA) - lease liability (CPC 06 (R2)/IFRS 16)	1,322	2,983
6.01.01.16	Unearned revenue (CPC 47/IFRS 15)	(388)	2,163
6.01.01.17	Changes in technical claims reserves	20	242
6.01.02	Changes in assets and liabilities	(88,210)	153,481
6.01.02.01	Interest earning bank deposits (Financial assets at fair value through profit or loss)	179,548	386,859
6.01.02.02	Receivables from operations with healthcare plans (clients)	(65,325)	(59,439)
6.01.02.03	Other accounts receivable, recoverable taxes and prepaid expenses	686	13,421
6.01.02.04	Inventories	(346)	(539)
6.01.02.05	Long-term assets (Non current)	(6,548)	(16,471)
6.01.02.06	Provision for Unsettled claims (UC)	7,803	(15,751)
6.01.02.09	Tax obligations (taxes payable)	(8,652)	(1,726)
6.01.02.10	Labor obligations, Suppliers, Advance from clients and Other accounts payable (Sundry debits)	23,182	5,755
6.01.02.11	Non-current liabilities	(56,996)	10,831
6.01.02.13	Income tax and social contribution paid	(168,537)	(166,922)
6.01.02.14	Social charges (Charges payable)	(282)	2,480
6.01.02.15	Trading on operations	5,304	(2,150)
6.01.02.16	Other technical reserves (OTHER)	1,953	(2,867)
6.02	Net cash from investment activities	(355,351)	(446,872)
6.02.01	Acquisitions of property, plant and equipment	(8,396)	(5,551)
6.02.02	Development of systems and software use licenses	(62,990)	(46,485)
6.02.06	Acquisition of investment	(44,819)	(17,416)
6.02.07	Dividends received from Subsidiaries and jointly-controlled subsidiaries	5,169	5,526
6.02.11	Interest earning bank deposits (Financial assets valued at amortized cost)	(244,315)	(382,946)
6.03	Net cash from financing activities	(339,815)	(429,976)
6.03.01	Dividends and interest on own capital paid	(169,777)	(261,159)
6.03.02	Acquisition of own shares - Treasury	(170,090)	(170,005)
6.03.04	Receipt of granting stock option	52	1,188
6.05	Increase (decrease) in cash and cash equivalents	(585)	(18,425)
6.05.01	Opening balance of cash and cash equivalents	16,422	34,847
6.05.02	Closing balance of cash and cash equivalents	15,837	16,422

Statements of changes in shareholders' equity/DMPL – 01/01/2022–12/31/2022 - Consolidated

Amounts in thousands of reais (R\$)

Account	Description	Paid-up capital	Capital reserves, options granted and treasury shares	Profit reserves	Retained earnings or losses	Other comprehensive income	Shareholders' equity	Non-controlling interest	Shareholders' equity - Consolidated
5.01	Opening balances	851,017	(251,028)	515,815	-	(724)	1,115,080	6,169	1,121,249
5.03	Adjusted opening balances	851,017	(251,028)	515,815	-	(724)	1,115,080	6,169	1,121,249
5.04	Capital transactions with partners	-	51,003	(185,702)	(249,257)	-	(383,956)	-	(383,956)
5.04.04	Treasury shares acquired	-	(163,046)	-	-	-	(163,046)	-	(163,046)
5.04.05	Treasury shares sold	-	52	-	-	-	52	-	52
5.04.06	Dividends	-	-	-	(60,000)	-	(60,000)	-	(60,000)
5.04.07	Interest on own capital	-	-	-	(69,257)	-	(69,257)	-	(69,257)
5.04.08	Goodwill/negative goodwill in capital transaction	-	(35,992)	-	-	-	(35,992)	-	(35,992)
5.04.09	Absorption of reserve for granting stock option	-	19,984	(19,984)	-	-	-	-	-
5.04.17	Additional dividend proposed	-	-	-	(95,913)	-	(95,913)	-	(95,913)
5.04.18	Additional dividend proposed	-	-	24,087	(24,087)	-	-	-	-
5.04.19	Put option in Subsidiary	-	40,200	-	-	-	40,200	-	40,200
5.04.20	Cancellation of treasury shares	-	189,805	(189,805)	-	-	-	-	-
5.05	Total comprehensive income	-	-	-	452,171	864	453,035	(4,810)	448,225
5.05.01	Net income for the period	-	-	-	452,171	-	452,171	(810)	451,361
5.05.02	Other comprehensive income	-	-	-	-	864	864	(4,000)	(3,136)
5.05.02.04	Translation adjustments in the period	-	-	-	-	864	864	(4,000)	(3,136)
5.06	Internal changes in shareholders' equity	-	-	202,914	(202,914)	-	-	-	-
5.06.01	Formation of reserves	-	-	202,914	(202,914)	-	-	-	-
5.07	Closing balances	851,017	(200,025)	533,027	-	140	1,184,159	1,359	1,185,518

Statements of changes in shareholders' equity/DMPL – 01/01/2021–12/31/2021 - Consolidated

Amounts in thousands of reais (R\$)

Account	Description	Paid-up capital	Capital reserves, options granted and treasury shares	Profit reserves	Retained earnings or losses	Other comprehensive income	Shareholders' equity	Non-controlling interest	Shareholders' equity - Consolidated
5.01	Opening balances	607,869	(25,021)	619,431	-	(639)	1,201,640	4,945	1,206,585
5.03	Adjusted opening balances	607,869	(25,021)	619,431	-	(639)	1,201,640	4,945	1,206,585
5.04	Capital transactions with partners	243,148	(226,007)	(295,469)	(188,506)	-	(466,834)	-	(466,834)
5.04.01	Capital increases	243,148	(48,392)	(194,756)	-	-	-	-	-
5.04.04	Treasury shares acquired	-	(177,049)	-	-	-	(177,049)	-	(177,049)
5.04.05	Treasury shares sold	-	1,188	-	-	-	1,188	-	1,188
5.04.06	Dividends	-	-	-	(95,754)	-	(95,754)	-	(95,754)
5.04.07	Interest on own capital	-	-	-	(52,232)	-	(52,232)	-	(52,232)
5.04.08	Goodwill/negative goodwill in capital transaction	-	(1,754)	-	-	-	(1,754)	-	(1,754)
5.04.09	Absorption of reserve for granting stock option	-	-	(100,713)	-	-	-	-	(100,713)
5.04.10	Supplementary dividend	-	-	-	(40,520)	-	(40,520)	-	(40,520)
5.05	Total comprehensive income	-	-	-	380,359	(85)	380,274	1,224	381,498
5.05.01	Net income for the period	-	-	-	380,359	-	380,359	981	381,340
5.05.02	Other comprehensive income	-	-	-	-	(85)	(85)	243	158
5.05.02.04	Translation adjustments in the period	-	-	-	-	(85)	(85)	243	158
5.06	Internal changes in shareholders' equity	-	-	191,853	(191,853)	-	-	-	-
5.06.01	Formation of reserves	-	-	191,853	(191,853)	-	-	-	-
5.07	Closing balances	851,017	(251,028)	515,815	-	(724)	1,115,080	6,169	1,121,249

Statement of added value - Consolidated

Amounts in thousands of reais (R\$)

Code of account	Account description	Current Year-to-date 01/01/2022–12/31/2022	Accumulated of the prior year 01/01/2021–12/31/2021
7.01	Revenues	1,960,117	1,890,588
7.01.01	Sale of goods, products and services	1,967,497	1,898,595
7.01.02	Other revenues	40,571	40,913
7.01.02.02	Sales of goods and services	21,892	16,406
7.01.02.03	Insurance	18,679	24,507
7.01.04	Provision/reversal of allowance for doubtful accounts	(47,951)	(48,920)
7.02	Inputs acquired from third parties	(1,052,363)	(999,528)
7.02.01	Cost of products, goods and services sold	(681,037)	(693,217)
7.02.02	Materials, energy, outsourced services and other	(9,487)	(12,234)
7.02.04	Other	(361,839)	(294,077)
7.02.04.01	Other operating revenues (expenses)	(21,188)	2,508
7.02.04.02	Sales expenses	(210,802)	(190,035)
7.02.04.03	Administrative expenses	(127,487)	(99,387)
7.02.04.04	Changes in provision for events/claims incurred but Not Reported (PEONA)	(2,342)	(6,921)
7.02.04.05	Claims - Technical reserves	(20)	(242)
7.03	Gross added value	907,754	891,060
7.04	Retentions	(37,023)	(63,582)
7.04.01	Depreciation, amortization and depletion	(32,395)	(57,760)
7.04.02	Other	(4,628)	(5,822)
7.04.02.01	Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	(4,628)	(5,822)
7.05	Net added value produced	870,731	827,478
7.06	Added value received as transfer	95,452	60,842
7.06.01	Equity in net income of subsidiaries	6,609	6,559
7.06.02	Financial revenues	88,843	54,283
7.07	Total added value payable	966,183	888,320
7.08	Distribution of added value	966,183	888,320
7.08.01	Personnel	193,922	186,491
7.08.01.01	Direct remuneration	157,267	146,887
7.08.01.02	Benefits	28,816	30,497
7.08.01.03	Severance Pay Fund (FGTS)	7,839	9,107
7.08.02	Taxes, duties and contributions	304,155	305,453
7.08.02.01	Federal	266,638	270,925
7.08.02.02	State	2,488	2,512
7.08.02.03	Municipal	35,029	32,016
7.08.03	Third-party capital remuneration	16,745	15,036
7.08.03.02	Rentals	569	(21)
7.08.03.03	Other	16,176	15,057
7.08.03.03.01	Financial expenses	16,176	15,057
7.08.04	Remuneration of own capital	451,361	381,340
7.08.04.01	Interest on own capital	69,257	52,232
7.08.04.02	Dividends	180,000	136,274
7.08.04.03	Retained earnings (losses) for the period	202,914	191,853
7.08.04.04	Non-controlling interest in retained earnings	(810)	981

Dear shareholders,

The Management of Odontoprev S.A. (Odontoprev or Company) submits for your examination the Financial Statements for the years ended December 31, 2022 and 2021.


Company's Overview and sector of activity

Odontoprev operates private dental plans.

Founded in 1987, Odontoprev has been the leader of its industry since the 1990s, with more than 8 million beneficiaries, providing quality oral health solutions. Odontoprev's technological platform is proprietary, with a world-class recognition. The Company has an accredited network of approximately 27 thousand dentists, covering over 2,500 municipalities, across the country.


Adaptations in the pandemic and Financial Performance

In 2022, net revenues grew 6.5% reaching R\$1,962 million, with an average ticket of R\$21 per member/per month and 8,317,964 members, net addition of 334 new members in the year. The portfolio consisted of 71% of corporate clients, with the remaining 29% dedicated to small and medium-sized enterprises (SMEs) and individuals.




The cost of services represented 40.2% of revenues in 2022, versus 39.3% in 2021. Selling and administrative expenses were 26.2% of the 2022 revenues.

The cash generation, as measured by Adjusted EBITDA, reached R\$576 million in 2022. As a portion of revenues, EBITDA margin was 29.4%.



Net income was R\$452 million, 18.9% higher than 2021. The Company ended 2022 with a net cash of R\$795 million, and zero debt.




The results demonstrate the Company's unique strategic positioning, with specialized operations for each client segment, optimizing the capture of opportunities for expansion and value creation.

	2006	2008	2010	2012	2014	2016	2018	2020	2022	CAGR
Net Revenues	182	318	685	955	1,156	1,365	1,592	1,765	1,962	16%
Average ticket (R\$/member/month)	12.25	12.07	12.87	14.33	16.07	18.58	20.43	20.47	20.72	3%
Number of members (000)	1,492	2,460	4,978	5,976	6,316	6,267	7,230	7,510	8,318	11%
EBITDA	46	76	154	227	305	300	415	544	576	17%
EBITDA Margin (%)	25.1	23.9	22.4	23.8	26.4	22.0	26.1	30.8	29.4	-
Net Income	17	55	121	146	195	216	285	361	452	23%
Market Cap	872	587	4,443	5,701	5,239	6,694	7,305	7,730	5,133	12%
ODPV3 Return (%)	22	-46	80	25	5	37	-13	-14	-21	12%
IBX-100 (%)	7	-42	3	12	-3	37	15	4	4	8%

Capital markets

In 2022, Odontoprev completed 16 years since the IPO in the B3's "Novo Mercado", and has reached, at the end of the year, a market cap of R\$5.1 billion. The total return to shareholders since the IPO equals 12% p.y., versus 8% p.y. of the IBX-100.



Since 2017, Odontoprev has been part of FTSE4Good Index's portfolio, a British index that assesses sustainability criteria in listed companies around the world. In 2023, the Company, for

the fourth consecutive year, was selected to compose the Bloomberg GEI, a global index of publicly traded companies committed to supporting gender equality through the development of policies, representation and transparency.

Corporate Governance

Odontoprev has been listed in the Novo Mercado, the highest level of Corporate Governance at B3. On top of the segment rules, the Company has differentiated practices, such as distinct Chairman from the CEO, Board of Directors without executive function and high Dividend Payout.

Statement of the Statutory Executive Board

In compliance with CVM, the Statutory Executive Board of Odontoprev declares that has discussed, reviewed and agreed with the opinions expressed in the Independent Accountants' report and with the financial statements for the year ended December 31, 2022, authorizing its disclosure.

Relations with independent auditors

The Company contracts KPMG Auditores Independentes to provide external audit services on financial statements and, for the purpose of CVM Regulatory Instruction no. 381/03, we declare that we have hired in 2022 for review of ECF, solvency and technical reserves auditing. The remuneration for the mentioned services was R\$300 thousand, which corresponded to 27% of the total financial of the total financial statements audit remuneration. The auditors comprehend that the additional services mentioned do not constitute an independence loss related to the financial statements audit service. We also highlight that eventual services not referred to external audit are previously submitted to the Audit Committee approval.

Barueri, March 01st, 2023.
Executive Officers

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

1. Operations and general information

Odontoprev S.A. (Company or Odontoprev) is a publicly-held corporation located at Alameda Araguaia, 2104, 21º andar, Alphaville – Barueri, São Paulo – Brazil.

The Company started operating on August 28, 1987 and is engaged in providing private dental care plans, the management, sale or availability of these plans to corporations and/or individuals, as well holding interests, as partner, shareholder or quotaholder in other civil or commercial companies, in commercial enterprises of any nature, in Brazil and/or overseas, and the management of its own assets and/or those of third parties.

The Company is classified as a dental operator in the tertiary sector, according to Normative Resolution (RN) 531 of May 02, 2022 of the National Agency of Supplementary Health (ANS).

The Odontoprev’s shares are traded on B3 under the ticker “ODPV3” and has been listed in the corporate governance segment called Novo Mercado (New Market) since December 01, 2006.

As of December 31, 2022, the Company declares that it is able to take to maturity the financial investments classified in the “held to maturity” category.

The Company holds direct and indirect interests in the following companies:

	Interest in capital (%)						
	December 31, 2022				December 31, 2021		
	Subsidiaries		Indirect associated company	Joint control	Subsidiaries		Indirect associated company
Direct	Indirect	Direct			Indirect		
COMPANIES:							
Odontoprev Serviços Ltda. (Odontoprev Serviços) ⁴	100.0	-	-	-	99.9	-	-
Easy Software S.A. (Easy Software)	-	51.0	-	-	-	51.0	-
Dental Partner Comércio de Produtos e Equipamentos Odontológicos Ltda. (Dental Partner) ²	-	100.0	-	-	-	99.9	-
SF 210 Participações Societárias S.A. (SF 210)	-	-	18.1	-	-	-	18.1
Clidec Participações S.A. (Clidec Participações)	-	90.6	-	-	-	90.6	-
Machiron Desenvolvimento de Sistemas S.A. (MaChiron) ³	-	-	20.0	-	-	-	-
TERTIARY SEGMENT DENTAL OPERATOR – RN 531 ANS:							
Brasildental Operadora de Planos Odontológicos S.A. (Brasildental)	-	-	-	25.0	-	-	25.0
Mogidonto Planos Odontológicos Ltda. (Mogidonto) ¹	-	-	-	-	100.0	-	-
NETWORK OF DENTAL AND RADIOLOGICAL CLINICS:							
Clidec - Clínica Dentária Especializada Cura Dars Ltda. (Clidec)	99.9	-	-	-	99.9	-	-
Boutique Dental Ltda. (Boutique Dental)	-	100.0	-	-	-	100.0	-
Clínicas Radiológicas Papaiz (Papaiz Group)	-	-	-	49.0	-	-	49.0
COMPANIES IN MEXICO:							
Odontored CV Sociedad Anônima de Capital Variable (Odontored)	100.0	-	-	-	60.0	-	-
Oprev Administradora Sociedad Anônima de Capital Variable (Oprev)	-	100.0	-	-	-	60.0	-

¹Subsidiary merged as of January 03, 2022.

²On May 24, 2022, it became a sole proprietorship, with subsidiary Clidec as its parent company.

³Indirect associated company acquired by Odontoprev Serviços on August 16, 2022.

⁴On September 06, 2022, it became a sole proprietorship, with Odontoprev as its parent company.

Odontoprev Serviços: established on December 3, 1999 for the provision of commercial advisory, consulting and business management services, as well as holding interests in other companies as a partner or shareholder.

Easy Software: established on November 3, 1993 as a subsidiary of Odontoprev Serviços for the development and licensing of software programs and holding interests in other companies, as a partner or shareholder.

Dental Partner: established on November 14, 2008 in the retail and wholesale markets, products and equipment, sanitizers, drugs, medicines, pharmaceutical inputs and related items, as well as the wholesale of medicines and drugs for human consumption, provision of services of warehousing, storage, loading, organization, custody of goods of any kind, provision of services of: (i) technical and administrative programming and organizing services; (ii) general management of goods and business; and (iii) collecting, sending or delivering mail, documents, objects or goods. On May 24, 2022, the company became a sole proprietorship, with Clidec, a subsidiary of Odontoprev, as its parent company.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reals, unless otherwise indicated)

SF 210: established on October 29, 2020, for the purpose of investing in other companies as a shareholder or quotaholder. The previous investment of Odontoprev Serviços in G2D was converted into this company, which was maintained as an Associated Company.

Clidec Participações: established on June 11, 2012 subsidiary of Clidec, its purpose is to hold interests in other companies as a shareholder or quotaholder and its shareholders are Clidec and two other minority shareholders.

MaChiron: founded in São Paulo in 2017, it specializes in integrating technologies through the application of artificial intelligence and machine learning to develop innovative solutions in the Dental area. On August 16, 2022, Odontoprev, through the subsidiary Odontoprev Serviços, exercised the right to convert a loan into a 10% equity interest under the Private Convertible Loan Instrument and Other Covenants entered into on February 5, 2020 in the total amount of R\$ 150 thousand and, additionally, made a contribution of R\$ 425 thousand, increasing the equity interest of Odontoprev Serviços to 20%.

Brasildental: established on March 12, 2014, it is a joint venture with BB Seguros Participações S.A. for the operation of private dental care plans in the management, sale or provision of such plans to corporations and/or individuals.

Clidec: established on July 2, 1970, its purpose is to provide clinical dental services.

Boutique Dental: established on October 21, 2011, as a subsidiary of Clidec, with the purpose of providing dental services and hold interests in other companies as a partner or shareholder.

Papaiz Group: holds interests in dental radiology clinics acquired on January 31, 2013, through Clidec Participações, a joint venture with the Fleury Group.

Odontored: established on August 13, 2009, in Mexico, for the development of dental care plans, including their operation, management and sale, as well as the provision of dental care services directly or indirectly through third parties. It was authorized to operate as insurance company specialized in health on June 06, 2013 and, on July 15, 2013, the National Commission of Insurance and Collaterals (CNSF) permitted operation of insurance against accidents and diseases in lines health and medical expenditures.

On October 3, 2022, the purchase of the remaining shares of the direct subsidiary, Odontored and its indirect subsidiary Oprev, was completed, pursuant to share put option exercised by minority shareholders in March 2020, the amount of which was already provisioned in the financial statements.

As a result of the transaction, Odontoprev and its subsidiaries now own all the shares issued by both subsidiaries located in Mexico.

Oprev: established on December 12, 2019 as a subsidiary of Odontoprev Serviços located in Mexico, for the provision of specialized services related to accidents and diseases, besides actuarial, financial, administrative, commercial and risk management services.

Mogidonto: established on June 24, 1976, it had as its corporate object the operation, management, administration and marketing of private health plans of dental care, own or of third parties.

On July 1, 2021, Odontoprev, in line with the material fact of December 22, 2020 acquired 100% of the capital of Mogidonto, headquartered in Mogi das Cruzes, São Paulo (Notes 10 and 12). The transaction was approved, without restrictions, by the National Agency of Supplementary Health (ANS) and the Central Bank of Brazil (BACEN).

The acquisition of Mogidonto has as its strategic focus to offer dental plans to medium and large companies.

On January 3, 2022, the Extraordinary General Meeting (EGM) approved the merger of the subsidiary Mogidonto into the Company, which, under current legislation, was approved by ANS on January 27, 2022. This operation did not have a material impact on the Company's financial statements.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

The breakdown of net assets for the merger is as follows:

Balance sheet

(In thousands of reais)

	December 31, 2021
	(merged assets)
ASSETS	
Current assets	6,766
Cash and cash equivalents (cash and bank balances)	49
Noncurrent	6,717
Financial assets at fair value through profit or loss (interest earning bank deposits)	6,020
Receivables from operations with health care plans	554
Goods and securities receivable	143
Non-current assets	8,399
Long-term assets	8,248
Property, plant and equipment	145
Intangible assets	7
TOTAL ASSETS	15,165
	December 31, 2021
	(merged assets)
LIABILITIES	
Current liabilities	1,858
Technical reserves for health care operations	956
Sundry debts	902
Non-current liabilities	8,673
Provisions for lawsuits (Contingencies)	1,509
Sundry debts	7,164
Shareholders' equity	4,634
Capital	531
Profit reserves	1,777
Retained earnings	2,326
TOTAL LIABILITIES	15,165

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Approval of financial statements

The authorization and approval to issue these individual and consolidated financial statements were given by the Board of Directors in a meeting held on March 01, 2023.

2. Description of significant accounting policies

2.1. Preparation basis

The Company's individual financial statements were prepared in accordance with accounting practices adopted in Brazil issued by the Accounting Pronouncement Committee (CPC) International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and in accordance with accounting practices adopted in Brazil. When required, and provided that are in compliance with CPCs and IFRSs, the financial statements consider the existing concepts in the standards issued by the National Supplementary Health Agency (ANS). Moreover, all relevant information specific to the financial statements, and only such information, is being evidenced, and corresponds to the information used by the Management in Company's administration.

Management also declares that these financial statements are being prepared following the going concern assumption.

2.1.1. Basis of consolidation

The following accounting policies are used in the preparation of the consolidated financial statements:

(a) Subsidiaries

These are all companies in which the Company has direct or indirect control in financial and operational management. The Company exercises control over an investee when it has: (i) power over the investee; (ii) exposure to, or rights over, variable returns deriving from its involvement with the investee; and (iii) capacity to use its power over investee to affect value of its returns. The Subsidiaries are consolidated as of the date control is transferred to Odontoprev.

The Company applies the acquisition method to account for business combinations, which are recorded at the fair value of transferred assets, liabilities and shareholders' equity calculated on the acquisition date. Costs related to the acquisitions are recorded in income (loss) for the year as incurred. The non-controlling interest in Subsidiaries is recognized in the financial statements proportionately based on the fair value upon acquisition.

The excess of the amount paid over the fair value of assets and liabilities assumed on the acquisition date of any equity interest is recorded as goodwill, after the allocation to tangible and/or intangible assets.

Investments of the Subsidiaries were eliminated in the consolidated financial statements, as well as the equity in the earnings of subsidiaries, in addition to the balances of assets, liabilities and income (loss) arising from transactions between such companies.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

(b) Investments in entities accounted for at the equity method

The investments of the Group in entities accounted for under the equity method refer to their interests in associated companies and joint ventures.

Associated companies: are all entities over which the Company has significant influence and exercises the power to participate in financial or operational policy decisions without having the control. Investments in associated companies are initially recognized at the cost value and subsequently, valued under the equity method.

Joint venture: are all entities that there is a sharing of control of an arrangement, which exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control. Such investments are valued under the equity method.

(c) Transactions eliminated in the consolidation

Intragroup balances and transactions, and any unrealized revenues or expenses (except for gains or losses on transactions in foreign currency) derived from intragroup transactions, are eliminated. Unrealized gains originating from transactions with investees recorded using the equity method are eliminated against the investment in the proportion of the Company's interest in the investee. Unrealized losses are eliminated in the same way as unrealized gains, but only up to the point where there is no evidence of loss due to impairment loss.

(d) Interest of non-controlling shareholders

The Company chose to measure non-controlling interest at their proportion interest in identifiable net assets of the acquiree on the acquisition date.

Changes to the Company's interest in a subsidiary that do not result in loss of control are accounted for as transactions from shareholders' equity.

2.2. Operating segments

The information is disclosed in a consistent manner with the internal report provided to the main operating and strategic decision maker of the Company, the Statutory Executive Board, which is responsible for resource allocation and performance evaluation of the operating segments (Note 18).

2.3. Functional currency and translation in foreign currency

The items included in the individual and consolidated financial statements are valued by using the main currency of the economic environment where the company operates (functional currency) and these financial statements are presented in Reais (R\$).

For the subsidiaries Odontored and Oprev (Note 1), the functional currency is the Mexican peso, which is translated into the currency of the Company for presentation purposes, using the closing exchange rate on the date of the respective balance sheet (current assets and liabilities), the date of the transactions (non-current assets and liabilities and shareholders' equity) and monthly average (revenues and expenses). Gains or losses in the translation of foreign-currency balances arising from the settlement of said transactions and translation of balances as of the balance sheet closing date are recognized in shareholders' equity.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

2.4. Current assets

2.4.1. Classification

(a) Cash and cash equivalents

Cash corresponds to cash and cash equivalents that represents funds without restriction for investment in the Company's operations with no restriction on immediate use (Note 5).

Cash equivalents are highly liquid assets held to meet short-term cash commitments, with original maturities of up to three months from their acquisition and insignificant risk of change in value (Note 5).

(b) Interest earning bank deposits (financial assets at fair value through profit or loss)

The financial asset is stated at fair value through profit or loss if the Company manages these investments and makes decisions on investment and redemption based on fair value according to the risk management and strategy of investments. Such financial assets correspond to interest earning bank deposits accounted for in current assets (Notes 4.1.1 and 6) and changes in fair value are recognized in income for the year.

(c) Interest earning bank deposits (financial assets valued up to maturity)

Acquired with the intention and financial capacity to hold them in the portfolio to maturity, classified in non-current assets on the maturity date is greater than 12 months and are recorded at cost on the acquisition date plus income (Notes 4.1.1 and 6).

(d) Receivables

They are non-derivative financial assets with fixed or determinable payments and not quoted in an active market, classified as current, except those maturing at least 12 months after balance sheet date (these ones are classified in non-current assets).

(e) Considerations receivable/premiums receivable

Regarding the contracts with fixed price, they are recorded and maintained in the Company in the balance sheet at the nominal value of the notes representing these credits, with a contraentry to the net consideration account in the result or to the provision for premiums/unearned considerations account in current liabilities, according to the risk coverage period of the contracts in force on the balance sheet date. For contracts at post-established prices, the considerations related to the recovery of expenses and, as revenue, the management fee, are recorded at the same moment of recognition of expenses with events. In the Consolidated, expenses with events and payments related to the recovery of expenses are eliminated, with only the management fee being presented as service revenue, as provided for in CPC 47 – Revenue from Contracts with Customers. In the Subsidiary Odontored the instruments representing these credits are recorded and kept in the policies representing these credits as contra-entry to the insurance account in profit or loss according to the risk coverage period of contracts in force.

2.4.2. Recognition and measurement

Financial assets are recognized at fair value, and amortized cost, and the costs, gains and losses arising from the transaction are recorded in contra-entry to statement of income in a specific account. Financial assets are written off when rights to receive cash flows from the investments have been expired or risks and rewards of the property that have been significantly transferred by the Company and its subsidiaries.

The Company evaluates, on the balance sheet date, whether there is objective evidence of loss (impairment) of a financial asset or group of financial assets (Note 2.4.4).

2.4.3. Fair value estimate

The Company applies CPC 46/IFRS 13 – Fair Value Measurement for financial instruments measured at fair value in the balance sheet, which requires disclosure of these measurements by the hierarchy level as presented below, and its financial risk management policy is to contract financial products available in the domestic market, whose market value can be reliably measured, seeking high liquidity to honor its future liabilities (Note 4.1.1).

- Level 1: prices quoted (not adjusted) in operating markets for identical assets and liabilities.
- Level 2: discounted cash flow methodology or other methodology for pricing the asset based on market data which are observable in the market.
- Level 3: inputs for the asset or liability that are not based on observable market variables.

2.4.4. Impairment of financial assets measured at amortized cost

The Company and its subsidiaries assess at the end of each reporting period whether there is evidence that the credit quality of an asset or group of assets is impaired, and impairment losses are incurred as a result of a loss event that has an impact on the estimated future cash flows of the asset or group of financial assets.

The Company and its Subsidiaries recognize impairment on consideration receivable considering invoices in arrears for more than 60 days for individual contracts and 90 days for collective contracts, plus an average loss percentage determined in a study of portfolio historic behavior. Losses with clients are recorded in account "provision for credit losses" in income.

Amounts overdue for more than 180 days, which Management does not expect to recover, are accounted for as effective loss.

By assessing the existence of objective evidence of impairment, the Company and its Subsidiaries measure the provision, reducing the book balance to its recoverable amount and recognizing the amount of the provision. If, in a subsequent period, the amount of the impairment loss decreases and such decrease can be related objectively to an event occurring after the impairment was recognized, the recovery and reversal are recognized in the statement of income.

The other types of financial assets classified as loans and receivables do not include assets classified as impaired. The maximum credit risk exposure on the report presentation date is the book value of each class of trade accounts receivable listed above.

2.4.5. Deferred acquisition costs (DAC)

These are directly incremental expenses related to the origin or renewal of contracts; that is, the amounts paid as agency services in collective agreements and commissions paid in individual annual contracts, both appropriated to income (loss) for a period of 12 months. Other expenses are recorded as selling expenses, as incurred.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

2.5. Non-current assets and liabilities

2.5.1. Long-term assets

(a) Deferred income tax and social contribution – assets and liabilities

Deferred tax assets with probable deductibility are recognized in respect to taxable temporary differences; that is, on those differences that will result in amounts to be excluded from the calculation of taxable income relating to income tax and social contribution of future years (Note 9.1).

Deferred taxes are measured at tax rates expected to be applied to temporary differences when they are realized or reversed.

The deferred tax assets and liabilities are recognized for tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable income will be available against which the tax loss carryforwards and credits can be utilized, or on different taxable entities but that there is an intention to settle current tax liabilities and assets on a net basis or tax assets and liabilities will be realized simultaneously.

Deferred income tax and social contribution assets are reviewed at each preparation date of financial statements and reduced when their realization is no longer probable.

(b) Judicial, tax and labor deposits

These refer to tax and civil lawsuits, monetarily restated according to the Special Settlement and Custody System (SELIC) index, and labor lawsuits monetarily restated according to savings (note 9.2).

(c) Investments (ownership interest)

These are represented by investments in subsidiaries, associated companies and joint ventures accounted for under the equity method based on their respective balance sheets (Note 10).

(d) Property, plant and equipment

(i) Construction in progress (property, plant and equipment)

Stated at acquisition cost, less respective accumulated depreciation calculated under the straight-line method, at the annual rates (Note 11).

Gains and losses from disposals are determined by comparing sales value with book value and are recognized in the income (loss).

(ii) Right of use (CPC 06 (R2) / IFRS 16)

Recognition of the present value estimate of payments of lease liabilities measured according to the requirements of CPC 06 (R2) / IFRS 16 — Leases (Notes 11 and 26).

(e) Intangible assets

(i) Goodwill on acquisition of investments

Refers to goodwill based on expected future profitability, paid on the acquisition of investments (Notes 12.1 and 12.2). It is represented by the positive difference between the amount paid for the acquisition of a business and the investee's net fair value of assets and liabilities of Subsidiary acquired and allocation of intangible items.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Goodwill is tested for impairment at least annually to evaluate the existence of any possible losses (Note 12.1), being accounted for at cost, less the accumulated by impairment, if any, which are not reversed.

(ii) Development of systems and software use licenses

Development expenditures related to software system and licenses that are directly attributable to the designs and testing of identifiable and unique software products controlled by the Company are recognized as intangible assets. They are amortized under the straight-line method over 60 months (Note 12.2). After the conclusion of projects, maintenance expenditures are recognized as expenses.

(iii) Allocated intangible assets

Amounts attributed to the brand, client portfolio and non-compete agreement arising from the acquisition of control in investees, which are amortized under the straight-line method, according to the terms identified in the valuation report (Note 12.2).

2.6. Impairment of non-financial assets

In accordance with CVM Resolution 639/2010, CPC 01 (R1)/IAS 36 - Impairment of Assets, assets are tested for impairment to: (i) verify whether there is any indication of impairment of assets; and (ii) measure any impairment of existing assets to complement or reverse the provision for impairment of assets, when applicable.

Assets subject to amortization/depreciation are reviewed on a regular basis to confirm their impairment or whenever events or changes in circumstances indicate that the book value may not be recoverable.

An impairment loss is recognized at the book value of the asset that exceeds its recoverable value (the greater value between the fair value of an asset less sale costs and value in use).

Assets with an indefinite useful life, such as goodwill, are not subject to amortization and are tested every year to confirm their impairment (Note 12.1).

2.7. Dental care plan and insurance contracts: Liability Adequacy Test (LAT)

The Company issues contracts for dental care and insurance, in which assumes insurance risk, which includes frequency of use and fluctuation of dental care costs (Note 4.2).

If any insufficiency is identified, the Company records the loss immediately as expense in income for the year, first reducing the acquisition costs, then forming additional provisions for insurance liabilities already recorded on the test date.

The last test was performed on the base date of December 31, 2022, in accordance with the business segments of the Company, according to CPC 11/IFRS 4 – Insurance Contracts. The flows were projected for an eight-year horizon adopting the cancellation rate observed in the portfolio, as provided for by Normative Resolution 528/2022, until the extinction of the mass adopting the permanence table calculated based on the operator's experience, and until the mass extinction adopting the BR-EMSsb-v.2021 mortality table, broken down by gender for exit due to death. Moreover, it has not presented insufficiency on the date of its realization. Therefore, there was no need for adjustments in the reserves recorded.

The assumptions adopted are detailed below:

- Deferred Acquisition Costs (DAC): allocated based on the distribution of total consideration for each segment.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

- Claim Ratio: this assumption was obtained from the relationship between assistance expenses and considerations, of contracts with pre-established prices from the database, in the period from January to December 2022.

Segment	Loss Ratio
Corporate	40.33%
Group Adhesion Benefits	61.08%
Co-responsibility assumed	39.98%
Individual	17.55%

- Factors for the development of paid events: this assumption was obtained from the paid event development triangles.
- Operating expenses (events): equivalent to 3.95%, calculated based on the relationship between the expenses of the cost centers directly involved with the payment flow of events (digital convergence, quality management, operations and finance) and the paid events.
- Operating expenses (consideration): 11.98% obtained in the ratio between administrative expenses of the other Cost Centers and the considerations.
- Taxes: taxes were considered in administrative expenses and correspond to the same period as the data in this information.
- Economic: the flows were brought to present value at the pre forward rate due to the absence of a collateral, with the following parameters:

Parameter	B0	B1	β_2	β_3	λ_1	λ_2
Factor	0.127777	0.001958	0.065851	-0.04706	2.603461	1.417619

2.8. Technical reserves for dental care operations

The Company constitutes the following monthly in current liabilities:

- (a) **Provision for Unearned Premiums (UP):** calculated on a “pro rata die” based on the considerations issued that became effective, being appropriated to income (loss) according to the risk coverage period (note 13.2).
- (b) **Provision for Unsettled Claims (UC):** classifies the events to be settled with dental care operations. Costs of services rendered are recorded based on claims reported by accredited service providers regarding the analysis of events covered by the plans, with a corresponding entry to the account “Known or reported events/claims” in the statement of income (Note 13.2).
- (c) **Provision for Incurred but not Reported Claims (IBNR):** actuarially estimated to cover payment of events that have already occurred and that are not yet known by the Company and, therefore, were not recorded in the accounting under Provision for Unsettled Claims (Notes 2.16 and 13.2). The calculation of IBNR was prepared according to actuarial methodology based on structuring of development triangles of claim records by occurrence of events (run-off triangles), which consider the experience period of events reported in the last 18 months.

2.9. Taxes and social security charges payable

- (a) **Corporate income tax (IRPJ) and social contribution (CSLL):** these are calculated based on criteria established by the legislation in force. IRPJ is calculated at the rate of 15% of taxable income, plus 10% as surtax on taxable income exceeding R\$ 240 per year and includes the corresponding tax incentive portion (Notes 14 and 24). The social contribution on net income is calculated at the rate of 9% on taxable income (Notes 14 and 24).

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

(b) Other tax obligations: these comprise mainly provisions for Social Integration Program (PIS) and Contribution to Social Security Financing (COFINS) which are calculated based on the criteria established by the legislation in force, using the rates of 0.65% and 4%, respectively, both over the billing less paid indemnifiable claims (Notes 14 and 19).

(c) Municipal tax liabilities: these comprise the provision for Service Tax (ISS) calculated based on criteria established by the legislation in force. ISS is calculated at rates between 2% and 5% (Notes 14 and 19).

(d) Social charges: charges payable (social contribution), corresponds to the contributions to the National Institute of Social Security (INSS) and the Government Severance Indemnity Fund for Employees (FGTS).

2.10. Commissions payable

Commitments with providers of intermediation services for plans, commissions and brokerage payable, which are mostly settled monthly (Note 21).

2.11. Suppliers of goods and services

These refer to unsettled obligations for goods or services acquired in the normal course of businesses, which are classified as current liabilities, except if the maturity is over 12 months after the balance sheet date, which are classified as non-current liabilities.

2.12. Sundry debts

Labor charges (salaries, vacation pay and fees), advances from clients, dividends and interest on own capital (Note 17.5), investments (Note 16.4) and other accounts payable (Note 15), lease liabilities and adjustment to present value (CPC 06 (R2) / IFRS 16) (Note 26).

2.13. Provisions for lawsuits (contingencies)

The Company and its subsidiaries assess their contingencies based on the requirements of the accounting pronouncement CPC 25/IAS 37 – Provisions, Contingent Liabilities and Assets, which for the lawsuits assessed as “probable losses” based on the assessments of internal and external legal advisors, the similarity with previous disputes, the complexity of the lawsuit and the opinion of legal courts, the Company recorded a provision for 100% of intended amounts (Note 16.1).

In addition, the administrative lawsuits assessed by consumer protection agencies (such as Procon), ANS and trade associations, with the application of monetary fines and pending judgment, are analyzed on a case-by-case basis. For these, individual estimates are established, and they may be changed according to the phase of the proceeding or the definition of the understanding by the agencies or associations. The Company and its subsidiaries and associated companies consider such administrative proceedings material, which impose the provision for these proceedings based on a possible loss and expected disbursements.

Lawsuits, related to tax obligations (legal, tax and social security), where the subject being contested is their legality or constitutionality, have their amounts fully recognized in the financial statements according to the risk characteristics of lawsuits and are restated according to the tax law.

2.14. Capital

Common shares are classified in shareholders' equity (Note 17.1).

The Company repurchases shares to maximize the generation of value for shareholders.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

2.15. Revenue recognition

(a) Net considerations / retained premiums

Revenue derived from operations related to private dental care plans in the form of previously agreed prices which have to be appropriated as the amount corresponding to the daily allocation pro rata die during the individual coverage period of each contract, since the first day of coverage (Notes 18 and 19). The installments referring to the considerations corresponding to the days of the future coverage period are recorded in the “Unearned premiums” account (Notes 2.8(a) and 13.2).

(b) Insurance

Corresponds to revenues from dental care insurance provided by subsidiary Odontored (Note 1) recognized in the statement of income according to the risk coverage (Notes 18 (d) and 19).

(c) Sales of goods and services

Revenues from sales of goods and services are allocated to the statement of income under the accrual basis as they meet their performance obligations (Notes 18 (d) and 19). In the modality of managed dental plans, Odontoprev manages dental expenses on behalf of its clients and is fully reimbursed by them, recording only its management fee as revenue from the operation.

(d) Financial

Revenues arises from interest earning bank deposits and inflation adjustment (Note 23).

2.16. Cost of services

The services provided by accredited professionals and dental clinics are recognized in the statement of income under the accrual basis, when claims covered by the plans are reported and analyzed, together with the recording of IBNR. Operating costs of the dental care network are recognized in the income (loss) on the accrual basis (Note 20).

The claims arising from the Subsidiary Odontored are recognized in income (loss) on accrual basis, based on the notices of claims received, together with the respective technical claims reserve (Note 20).

2.17. Employee and management benefits

Regarding the employee and management benefit program, even in the form of financial instruments, the Company and its subsidiaries adopt the following procedures: (i) profit sharing and long-term incentive program (ILP) are classified in operating expenses, according to CPC 33 (R1)/IAS 19 – Employee Benefits.

2.18. Dividends and interest on own capital

The distribution of dividends and interest on own capital to Odontoprev’s shareholders is recognized as a liability in the financial statements based on the Company’s Bylaws that establish a compulsory minimum dividend of 50%, calculated over net income. Any amount that exceeds the minimum required, as long as it is not paid, is recorded in shareholders’ equity, in the account “additional dividend proposed”, until it is approved by the shareholders at the Annual General Meeting (AGM) (Note 17.5).

2.19. Earnings per share

The Company calculates basic and diluted earnings per share in accordance with CPC 41/IAS 33 – Earnings per Share (Note 25).

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

2.20. Standards and interpretations

The main standards and interpretations of standards that will affect the Company and its subsidiaries are summarized below:

CPC 48/IFRS 9 - Financial Instruments (Adoption)

The rule came into force on January 1, 2018, with its application postponed to January 1, 2023 for entities whose core business refers to insurance operations. The Odontoprev Group, as it is mostly composed of operations in which it assumes insurance risks, made its first-time adoption on January 1, 2023.

(a) Classification of financial assets

The standard introduces the classification of financial assets based on their business model, as follows: amortized cost, fair value through other comprehensive income (FVTOCI) and at fair value through profit or loss (FVTPL). The Odontoprev Group classifies financial assets using the SPPI (Solely Payments of Principal and Interest) Test, which consists of identifying whether the profitability of financial assets is linked to the value of principal plus interest as a function of the time value of money.

Assets that pass the SPPI test shall be measured at amortized cost or fair value through other comprehensive income depending on the way that the Group manages it. Assets managed with the purpose of receiving cash flows are measured at amortized cost. Assets managed with the purpose of obtaining cash flows through asset maintenance and sales are measured at fair value through other comprehensive income. Assets that did not pass the SPPI test are classified as fair value through profit or loss.

The Odontoprev Group's portfolio consists of public securities, funds and quotas measured at amortized cost or fair value through profit or loss. Despite the new behavior of liabilities under IFRS 17, it was not necessary to reclassify assets under the IFRS 9/CPC 48 standard to improve portfolio protection between assets and liabilities, since the impacts caused by changes in rates and financial assumptions on liabilities do not have a significant impact on the Company's income (loss).

(b) Impairment

IFRS 9/CPC 48 changes the calculation of the asset impairment by defining the expected loss based on macroeconomic indicators. The new loss calculation methodology is applicable for assets that have credit risk. The Odontoprev Group has government bonds issued in local currency in the portfolio and, therefore, the Company considers that there is no credit risk and for such assets there will be no calculation of expected losses. The group's other financial assets, including funds and quotas, are measured at fair value through profit or loss and, in accordance with regulations, there is no loss calculation.

CPC 50/IFRS 17 - Insurance Contracts

IFRS 17, issued in May 2017 replacing IFRS 04 – Insurance Contracts, provides for changes in the way of measuring, recognizing and disclosing asset contracts, establishing specific methodologies for each type of contract. The application of this standard is mandatory for entities that issue insurance contracts for the years starting from January 1, 2023.

IFRS 17 aims to ensure that institutions provide relevant information in a way that represents the nature of insurance contracts and provides a basis for users of financial statements to assess the effects that contracts have on the financial position, financial performance and an institution's asset flows. For this purpose, several requirements are established, which companies must understand, interpret and apply, according to the characteristics and nature of their insurance contracts.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

(a) Estimated impact on shareholders' equity of the adoption of CPC 50/IFRS 17

Management evaluated the impact of the first-time adoption that the new standard will have on its financial statements and estimated that it will be a reduction of approximately R\$ 39 million (3%) in shareholders' equity as of January 1, 2023, considering the changes and required adjustments.

Considering that the Company disclosed known or reasonably relevant information, it was possible to estimate the impact that the application of CPC 50/IFRS 17 will have on its financial statements in the initial application period that were available when the financial statements for 2022 were authorized for issue.

(b) Contracts within the scope of the standard

The standard defines that every contract that meets the definition of insurance (written insurance, accepted and issued reinsurance and investment contracts with discretionary participation) must be measured in accordance with its guidelines. Odontoprev assessed its issued insurance contracts and considered that the Company's prepayment products are within the scope of CPC 50/IFRS 17.

Prepayment products are those in which the monthly fee is calculated in advance based on the coverage contracted by the contracting party (individual or legal entity) of the dental plan and, therefore, there is a transfer of insurance risk to the Company.

Regarding post-payment products, they are outside the scope of CPC 50/IFRS 17 as there is no insurance risk and, therefore, they will be measured in accordance with the rules provided for by CPC 47/IFRS 15 as a service agreement.

(c) Level of contract aggregation

The standard defines that insurance contracts must be grouped based on similar risks and joint management, which are segregated by types (annual cuts) and then broken down into categories: (i) contract groups that are onerous on initial recognition and (ii) contract groups that, on initial recognition, have no significant possibility of becoming onerous in the future. Finally, in addition to the aforementioned contract groups, there are still remaining contract groups in the portfolio.

Under the standard, insurance contracts are considered onerous at the initial recognition date if the fulfillment cash flows allocated to the contract, any previously recognized insurance purchase cash flows and any cash flows arising from the contract at the recognition date are a net outflow, i.e. representing a loss that must be recognized in income (loss) for the net outflow to the onerous contract group that results in the book value of the liability for the group being equal to the cash flows from compliance and the contractual insurance margin of the group being zero. Since it represents a loss upon initial recognition, unlike non-onerous contracts, which negatively impact income (loss), this must be considered, according to the standard, separately, so that the organization can manage them more precisely and know exactly the individual impact of the onerousness of the contracts in its financial statements.

Each contract within the scope of the standard was evaluated to classify the groups according to the definitions of the new standard. No onerousness was found in the Company's contract groups. Therefore, there was no impact in terms of results compared to IFRS 4.

(d) Contract limits

According to CPC 50/IFRS 17, for insurance contracts the cash flows are within the limit of the insurance contract if they result from substantive rights and obligations that exist during the reporting period in which the entity can demand the payment of consideration from the contract holder or where the entity has a substantive obligation to provide insurance coverage to the contract holder.

Thus, for Individual Plan portfolios, the contract limit will be the moment when the insured chooses to leave the contracted plan, since the insurer does not have the prerogative to cancel the contract unilaterally. This limit is reflected in the flow through the permanence table. As for the Corporate Collective and Membership Collective Plan portfolios

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

(CORP and PME), the contract limit, when we look at the payment projection, is monthly, since the contract is renewed monthly and can be canceled by both parties involved. The calculation of the Provision for Remaining Coverage (PCR) of contracts measured by the simplified model (PAA) is similar to the calculation of the current PPCNG. The PCR concept and measurement models will be defined below.

Odontoprev evaluated the limits of its insurance contracts issued in the light of the concepts brought by CPC 50/IFRS 17 and did not identify material changes when compared to those already applied under CPC 11/IFRS 4.

(e) Segregation of contract components

IFRS 17 distinguishes three different types of components that must be accounted for separately if certain criteria are met:

- Embedded derivatives;
- Investment component; and
- Commitments to transfer specific unsafe goods or services.

Through the analysis of the Company's insurance contracts, no components have been identified that would need to be treated separately. Within the business collective legal entity segment, there is a plan, which presents the service component called Concierge. The flow of this service is highly related to the insurance flow, which does not make it necessary to separate this component. Thus, it can be assessed under CPC 50/IFRS 17.

(f) Measurement of contracts

The Liability for the Remaining Coverage (PCR) represents the entity's obligation to investigate and pay valid claims for insured events that have not yet occurred. The PCR also covers the entity's obligation to pay amounts under existing insurance contracts that are related to coverage of contracts not yet rendered (obligations related to the future provision of insurance contract services) and any components of investments or other amounts that are related to the provision of services under the insurance contract and that have not been transferred to liability for claims incurred. The PCR reserve can be calculated based on three methodologies: General Model (BBA), Variable Rate Model (VFA) and Consideration Allocation Model (PAA).

The General Model – BBA of CPC 50/IFRS 17 requires that insurers and reinsurers measure their insurance contracts, at the initial moment, by the total estimated value of expected cash flow, adjusted by the time value of money and by the explicit risk related to non-financial risk, in addition to the contractual insurance margin. Odontoprev expects the application of the general model for the contracts of Individual Plans, since, in addition to being the standard model of the standard, the contracts are characterized by being of long term.

In addition to the General Model, CPC 50/IFRS 17 provides for, as a way of simplifying the measurement process, the Consideration Allocation Model - PAA. This simplified model is applicable, according to the standard, to contracts with a coverage period of up to one year or those with recognition of income (loss) similar to the General Model. Odontoprev applies the simplified PAA model for groups of corporate collective membership plans (CORP and PME). However, considering that such groups of contracts have short-term liabilities, but limits above one year, as required by CPC 50/IFRS 17, it was necessary to apply the adherence test so that the application of the simplified measurement approach is allowed. In this test, the Company needed to assess whether the measurement, if using the simplified PAA approach, would result in a measurement similar to that considered by applying the standard modeling - BBA. Adherence tests must be carried out annually.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

(g) Estimate of future cash flows

The items considered as future cash flows, both received and paid by Odontoprev within the limit, are as follows: (i) considerations, cancellations are reflected, in long-term contracts, through the permanence rate (permanence table) of the brand/product; (ii) payments, including events, events occurred and not reported, and all future events; (iii) allocation of cash flows from insurance purchases attributable to the portfolio to which the contract belongs, which should be understood as a commercial expense; (iv) costs of maintaining and managing contracts, such as costs of collecting consideration, processing of contractual amendments and costs of processing events, which should be understood as other operating costs; (v) allocation of fixed and variable overhead expenses (such as accounting costs, human resources, information technology and support, rent and maintenance), called administrative expenses, directly attributable to the fulfillment of contracts and transaction-based taxes.

(h) Discount rate

Discount rate is the rate used to reflect the time value of money. This can be built based on two methodologies: Top-Down or Bottom-Up. In the Top-Down methodology, the calculation of the Discount Rate is performed through the analysis of the behavior of the return of the assets specifically from the perspective of the ALM (Asset Liability Management), the calculation of the IRR (Internal Rate of Return) of the asset and, later, a discount curve is constructed by interpolating the IRR of these assets. ALM represents a risk management technique that aims to avoid the mismatching between assets and liabilities. On the other hand, in the Bottom-Up methodology, the calculation of the Discount Rate is carried out based on a risk-free rate, which in Brazil is considered the ETTJ, to which the risk of illiquidity is added. The risk of illiquidity measures the risk exposed in the event of non-receipt of a certain coupon, that is, it measures the extent to which this has an impact on the fulfillment of the insurer's obligations.

The discount rate used by Odontoprev to discount cash flows for all products is the Bottom-Up rate. Compared to what had been used previously, considering the guidelines provided for by IFRS 4, there were no significant changes in its value since, in the analyzed periods, considering the Company's ALM policy, the risk of illiquidity found was null.

(i) Risk adjustment (RA)

The Risk Adjustment (RA) is the adjustment made by the entity in the estimate of the present value of future cash flows to offset uncertainty about the amount and timing of cash flows arising from non-financial risk as the entity complies with the insurance contract. According to CPC 50/IFRS 17, the entity must disclose the confidence level used to determine the non-financial risk adjustment. However, if an entity uses a technique other than the confidence level to calculate the risk adjustment, it must disclose which technique is used and the equivalent confidence level of that technique.

Considering the availability of information from Odontoprev, since it does not have an internal risk model for applying the confidence level methodology, the Cost of Capital methodology is applied to calculate the non-financial risk adjustment. Under this Cost of Capital calculation approach, the RA is the cost of providing an amount of eligible funds equal to the capital required to support insurance commitments over the life of the contract. This methodology stands out for its simplicity in the calculation to obtain regulatory capital and for the fact that such methodology is used in different countries, which have risk-based regulations. Among the disadvantages of the cost of capital method are the need to calculate the cost of capital for non-financial risks and the complexities of both projecting future capital requirements and estimating the equivalent percentile. Thus, the percentile that represents the confidence level equivalent to the cost of capital used by Odontoprev is 59%.

The RA concept is a new concept introduced by CPC 50/IFRS 17 as part of the measurement of insurance contract liabilities. Therefore, the total of its effect on these liabilities represents a change in relation to the previous standard (CPC 11/IFRS 4).

(j) Allocation of the contractual service margin (CSM)

The value of the contractual insurance margin for each group of insurance contracts must be recognized in income (loss) in each period to reflect the insurance services provided. The amount is calculated by identifying the coverage units, allocating them to the contractual insurance margin at the end of the period, equally for each coverage unit

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

provided in the current period and expected to be provided in the future, and recognizing the amount allocated to units of coverage provided in the period in income (loss).

For groups of contracts measured using the General Model (BBA), the entity must recognize the contractual insurance margin over the life of the group of contracts in a systematic manner that reflects the transfer of insurance benefits under the contract. It is worth highlighting that the CSM is only measured for contracts that follow the BBA or VFA methodology. Therefore, only individual contracts measure the CSM.

Odontoprev has applied judgment and considered all relevant facts and circumstances to determine a systematic and rational method for estimating the insurance contract services provided for each group of contracts. The bases for determining the amount of coverage provided for each product for the CSM appropriation are determined based on the outflows, number of policyholders or volume of reserves, depending on the contract group. Interest on CSM will be recognized using the discount curve upon initial recognition.

Regarding CPC 11/IFRS 4, as well as the RA, there were significant changes compared to CPC 50/IFRS 17, and, from now on, revenue will be allocated to income (loss) more slowly, as its allocation will be based on the service provision.

(k) Transition

Under the standard, an entity must apply the Full Retrospective Approach to insurance contract groups at the transition date. The entity must not adopt the full retrospective approach when this is unfeasible. In that case, the entity needs to choose between the Modified Retrospective Approach or the Fair Value Approach. However, if the entity does not have reasonable and sustainable information to measure contracts based on the Modified Retrospective Approach, it must mandatorily use the Fair Value Approach. The three measurement forms are detailed below:

Full retrospective approach

The full retrospective method consists of measuring insurance contracts since their issuance, requiring the company to have available data to carry out cash flow projections, calculate the discount rate and Risk Adjustment from the initial recognition of the contracts. According to CPC 50/IFRS 17, the entity must:

- Identify, recognize and measure each group of insurance, reinsurance and investment contracts with discretionary participation as if IFRS 17 had been always applied;
- Identify, recognize and measure any assets for insurance purchase cash flows as if IFRS 17 had always been applied (except for the fact that the entity is not required to apply the impairment assessment before the transition date);
- Derecognize any existing balances that would not exist if CPC 50/IFRS 17 had always been applied (including some deferred acquisition costs, provisions for fees attributable to existing insurance contracts and intangible assets related to clients of acquired insurance contracts);
- Recognize any net difference resulting in shareholders' equity

In summary, the characteristics are the following:

- Grouping of contracts: grouping by year of underwriting and characteristics of the time of initial recognition (onerous, non-onerous and non-onerous with the possibility of becoming onerous);
- Initial expected cash flows: estimate of expected cash flows at the time of sale of the contract, based on the assumption at that time;
- Discount rate: use of the discount curve obtained in accordance with the requirements of CPC 50/IFRS 17 (Top Down x Bottom-Up) with information on the moment of initial recognition;
- Risk adjustment: calculation based on assumptions in effect upon initial recognition.

Modified retrospective approach

The objective of the modified retrospective approach is to achieve the closest outcome to full retrospective approach possible using reasonable and supportable information available without excessive cost or effort. This approach should only be applied if the entity does not have reasonable and supportable information to apply the Full Retrospective Approach. The Modified Retrospective method allows the application of some simplifications, including:

- **Initial evaluations:** possibility of applying the grouping of contracts for different years of underwriting (if there is no reasonable information);
- **Cash flows:**
 - (a) Flows prior to the transition date: actual flows observed in the contracts since the moment of their issuance are considered (premiums, expenses, claims, etc.), including those that correspond to contracts that are not currently effective.
 - (b) Flows after the transition date: future flows are calculated based on realistic assumptions obtained with current information.
- **Risk adjustment:** it can be calculated considering current assumptions and released with current products.
- **Discount rate:** it is possible to use the reference curve equivalent to the curve required in at least 3 previous years. If not, adjust a reference curve with the average spread between the required curve.

Fair value approach

The fair value approach has the following transition features:

- **Grouping of contracts:** the grouping of contracts of different years of underwriting is allowed;
- **Initial expected cash flows:** it allows obtaining future cash flows based on realistic assumptions corresponding to the moment of evaluation;
- **Discount rate:** use of the discount curve obtained according to the requirements of CPC 50/IFRS 17 (Top-Down X Bottom-Up) with information upon transition;
- **Risk adjustment:** calculation based on assumptions in effect upon transition;
- **Application of OCI (Other comprehensive income):** revenues and expenses accrued in ORA on the transition date (if the ORA option is applied).

For contract groups measured using the simplified model (PAA), CORP and PME groups, the transition methodology will be the Total Retrospective.

As for the Individual group, measured by the BBA, the methodology used will be the Fair Value, specifically for contracts issued until 2020. For contracts issued from 2021 onwards, the transition methodology will be the Total Retrospective. The Fair Value methodology will be applied in the indicated period due to the lack of consistent data available for the application of the Total Retrospective methodology by group of contracts. Therefore, the Retrospective Total methodology is applied from the period in which the contracts issued have all the necessary information for their measurement and accounting by group of contracts.

It is worth highlighting that based on the fair value methodology, the contractual insurance margin (CSM) represents the difference between the Fair Value calculated by the organization and the fulfillment cash flows under CPC 50/IFRS 17 on this date, added to the non-financial risk (RA) adjustment.

A summary of the contract groups and transition methodologies used is provided below:

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Transition	
Contract group	Transition methodology
Plans - Individual (issue until 2020)	<i>Fair value</i>
Plans - Individual (issue as of 2021)	Full retrospective
CORP Collective Plans	Full retrospective
PME/SPG/MPE Collective Plans	Full retrospective

The fair value transfer amounts will be obtained through the CPC 46/IFRS 13 revenue approach.

(l) Disclosure and presentation

CPC 50/IFRS 17 requires extensive new disclosures about amounts recognized in the financial statements, including detailed contract reconciliations, effects of newly recognized contracts and information about the expected CSM emergence pattern, as well as disclosures regarding significant judgments made when applying the CPC 50/IFRS 17. There are also expanded disclosures about the nature and extent of risk of insurance contracts, reinsurance contracts and investment contracts with discretionary participation. Disclosures will generally be made at a more granular level than under CPC 11/IFRS 4, providing more transparent information for assessing the effects of contracts on financial statements.

3. Estimates and accounting judgments

For the preparation of financial statements, Management used judgments, estimates and assumptions that affect the application of accounting policies of the Company and Consolidated and the reported amounts of assets, liabilities, revenues and expenses. However, actual results may differ from these estimates.

Estimates and assumptions are reviewed on a continuous basis and their impacts are recognized on a prospective basis in accordance with CPC 23/IAS 8 – Accounting Policies, Changes in Accounting Estimates and Errors.

(a) Judgments

Information about judgment referring to the adoption of accounting policies which impact significantly the amounts recognized in the financial statements are included: (i) evaluation of insurance liabilities (notes 2.8 and 13), (ii) evaluation of provisions for tax, civil and labor contingencies (notes 2.13 and 16.1).

(b) Uncertainties on assumptions and estimates

Information on uncertainties as to assumptions and estimates that pose a high risk of resulting in a material adjustment including: (i) calculation of financial assets' impairment (notes 2.4.4 and 6), (ii) evaluation of deferred tax credits (notes 2.5.1 (a) and 9.1), (iii) calculation of non-financial assets' impairment (notes 2.5.1 (e), 2.6 and 12.1) and (iv) calculation of right-of-use, lease liabilities and respective adjustment to present value (notes 2.5.1 (d), 2.12 and 26).

4. Risk management

The main risks arising from the businesses of the Company and its subsidiaries listed below are managed by different departments and comprise several strategies and policies considered appropriate by Management.

Risk management policies and strategies are monitored by the Audit Committee, created and installed on March 26, 2010, by determination of the Board of Directors and in accordance with the Company's Bylaws. Since October 2022,

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

the Company has implemented the Risk Management Committee, a body subordinate to the Presidency that assesses and monitors risk exposures, supporting the Audit Committee.

4.1. Financial risk factors

4.1.1. Market risk (interest rate)

Arises from the possibility that the Company and its subsidiaries be subject to changes in interest rates that may generate impacts on the fair value of the interest earning bank deposits portfolio.

The Company and its subsidiaries adopt the policy to invest in short-term funds and federal government bonds, complying with internal assessment criteria and limits established based on qualitative and quantitative information, including the requirement to allocate funds in compliance with RN 521/2022 from ANS, to guarantee the technical reserves. The interest earning bank deposits portfolio of the Company and its Subsidiaries is, for the most part, exposed to real interest in instruments post-fixed to inflation measured by the IPCA.

As of December 31, 2022, of the total funds of the Company and Consolidated, 86.0% and 83.7% (58% and 55.9% as of December 31, 2021) are invested in federal government bonds, 14% and 16.3% (42% and 42.6% as of December 31, 2021) are invested in investment funds, substantially impacted by changes in the SELIC/CDI rate.

According to the CPC 40(R1)/IFRS 7 - Financial instruments: disclosures, the Company and its Subsidiaries performed a sensitivity analysis of their financial instruments as highlighted in the table below:

Company										
December 31, 2022 (Note 6)										
	Indexed to SELIC/CDI		Indexed to IPCA + fixed rate			Earnings				Total financial investments
	SELIC/CDI (p.a.) ¹	Fixed income from inv. fund	Fixed rate ³	IPCA (p.a.) ¹	NTN-B	Fixed rate ³	NTN-F	Fixed rate ³	LTN	
Level hierárquico ²	-	2	-	-	2	-	2	-	2	-
Investments	-	104,614	-	-	471,331	-	124,384	-	48,087	748,416
Projection of profitability in the next 12 months:										
Probable	11.75%	12,291	4.32%	5.30%	45,357	9.52%	11,847	13.02%	16,198	85,693
2.0 p.p. decrease	9.75%	10,199		3.30%	35,930		11,847		16,198	74,174
3.0 p.p. decrease	8.75%	9,153		2.30%	31,217		11,847		16,198	68,415
2.0 p.p. increase	13.75%	14,384		7.30%	54,783		11,847		16,198	97,212
3.0 p.p. increase	14.75%	15,430		8.30%	59,497		11,847		16,198	102,972

¹Based on the FOCUS report disclosed by the Central Bank of Brazil on March 30, 2022.

²Hierarchical level classification (note 2.4.3).

⁴The investment in question is not exposed to fluctuations in indices as it has fixed yields.

Consolidated											
December 31, 2022 (Note 6)											
	Indexed to SE-IC/CDI		Indexed to Mexican bond		Indexed to IPCA + fixed rate			Earnings			Total financial investments
	SELIC/CDI (p.a.) ¹	Fixed income from inv. fund	BM (p.a.) ³	CETES	Fixed rate ⁴	IPCA (p.a.) ¹	NTN-B	Fixed rate ⁴	NTN-F	Fixed rate ⁴	
Level hierárquico ²	-	2	-	2	-	-	2	-	2	-	-
Investments	-	127,381	-	8,211	-	-	471,331	-	124,384	-	48,087
Projection of profitability in the next 12 months:											
Probable	11.75%	14,967	9.99%	820	4.32%	5.30%	45,357	9.52%	11,847	13.07%	16,198
2.0 p.p. decrease	9.75%	12,419	7.99%	656		3.30%	35,930		11,847		16,198
3.0 p.p. decrease	8.75%	11,145	6.99%	574		2.30%	31,217		11,847		16,198
2.0 p.p. increase	13.75%	17,514	11.99%	984		7.30%	54,783		11,847		16,198
3.0 p.p. increase	14.75%	18,788	12.99%	1,067		8.30%	59,496		11,847		16,198

¹Based on the FOCUS report disclosed by the Central Bank of Brazil on March 30, 2022.

²Hierarchical level classification (note 2.4.3).

³Rates available from the Central Bank of Mexico.

⁴The investment in question is not exposed to fluctuations in indices as it has fixed yields.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

The Company adopted in its valuation the percentages of 2.0 pp. and 3.0 pp., considering changes in the Selic rate in the last 12 months and the exposure of its investments to this variation to be reasonable. Of the total interest earning bank deposits, R\$ 748,416 refer to the Company and R\$ 30,978 refer to the other Subsidiaries.

	December 31, 2022			December 31, 2021			Ratings of financial institutions					
	Company	Consolidated	Average yield	Company	Consolidated	Average yield	Fitch		Moody's		S&P	
			% CDI			% CDI	ST	LT	ST	LT	ST	LT
Banco Santander (Brasil) S.A.	-	-	-	-	949	-	F1 +	AAA	P-3	Baa3	brA-1+	brAAA
Itaú Unibanco S.A.	-	-	-	-	43	-	F1 +	AAA	PN	Ba1	brA-1+	brAAA
Banco Bradesco S.A.	104,614	127,381	94.9%	289,303	303,481	104.2%	F1 +	AAA	PN	Ba1	brA-1+	brAAA
Brazilian Government	643,802	643,802	72.6%	399,487	399,487	106.0%	-	BB-	-	Ba2	-	BB-
Mexican government	-	8,211	-	-	10,667	-	-	BBB-	-	Baa2	-	BBB
	<u>748,416</u>	<u>779,394</u>		<u>688,790</u>	<u>714,627</u>							

4.1.2. Credit risk

Arises from the possibility of the Company and its direct and indirect subsidiaries not receiving the amounts arising from interest earning bank deposits, considerations and services provided (Notes 6, 7 and 19). The credit policy takes into consideration the specific characteristics of dental care plan operations and is focused on maintaining the flexibility required by market conditions. The Company constantly monitors its receivables and calculates the allowance for doubtful accounts (Note 2.4.4).

None of the Company's clients represents 10% of revenues or more of the total of the respective class of financial assets.

4.1.3. Liquidity risk

The liquidity risk management objective is to monitor the settlement terms of the rights and obligations of the Company and its subsidiaries and of their financial instruments, preparing projected cash flow analysis and periodically reviewing the liabilities assumed and the financial instruments used, mainly those related to assets that guarantee the technical reserves.

The receivables comprising the Company's and its subsidiaries' cash flows arise mainly from corporate and individual contracts in prepayment model, which establish the settlement of monthly payments mainly at the first fortnight of each month for use of benefits. On the other hand, the payments to the accredited chain, the main suppliers, occur mostly at the beginning of the month. These are current assets and liabilities.

4.2. Underwriting risk

Underwriting risk is the uncertainty measure related to an adverse economic position that goes against the operator's expectation at the time of the preparation of its underwriting policy regarding the uncertainties existing in the estimate of the technical reserves and provisions related to pricing. Odontoprev's business model is based on the clients' monthly or yearly payments and is exposed to a risk of insurance and dental materials cost fluctuation, taking into consideration that in the dental care plan sector the risk is limited to the frequency of utilization and the low cost of the treatments provided.

In the development and structuring of dental care plans, the following factors are considered:

Risk model: prepaid, per capita monthly rate;

Service model: defines how the beneficiary will receive contracted dental care: accredited chain; free choice; own service units; and exclusive dental offices in the client's establishment;

Enrollment model: entire group (mandatory enrollment) or part of the group (free enrollment);

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Coverages: all the dental care treatments whose costs are totally or partially covered in the dental care plan contracted, the ANS determines minimum dental care coverage;

Usage moderating factors: co-participation and grace periods;

Fees: remunerations for professionals of accredited chain and several levels of free choice reimbursement and own clinics;

Dental material: value added to the risk premium and destined to the expenses with dental material of the loyalty program for the professionals of the accredited network.

The fluctuation also has direct impact on dental care plans, as they may rise as a result of usage volume, legislation, and increase in dental material values.

To manage the underwriting risk, the Company has its own system that allows the individual assessment of all treatments carried out, as well as specialized departments that work with estimating technical reserves and pricing dental plans.

Collective contracts have average term of 24 months, with clause stipulating fine for breach of contract and annual adjustments of rates practiced using claim rate (cost of services in the last 12 months, divided into the sales revenue) and/or inflation adjustment at official rate established in contract. They are also traded, with validity period of 12 months automatically renewable by an indeterminate period of time, with clause establishing fine for rescission and adjustment clause using official rate established in contract.

The Company constantly follows-up its contracts to minimize risks and ensure its financial balance.

In general, claim ratio between 40% and up to 60% permits contribution margin (gross income less trading expenses divided by sales revenue) able to support the Company's administrative expenses. As of December 31, 2022, the claim ratio of the Company and Consolidated was 38.6% and 38.4%, respectively (39.8% and 39.2% as of December 31, 2021, respectively) and contribution margin of 50.2% in the Company and 50.5% in the Consolidated (49.9% and 50.3% on December 31, 2021, respectively).

Increase/decrease in contribution margin (Notes 19, 20, 21)

	Company						Consolidated					
	Period ended December 31, 2022		Changes in loss ratio				Period ended December 31, 2022		Changes in loss ratio			
			Equal to 60%		Equal to 40%				Equal to 60%		Equal to 40%	
Sales revenue	1,876,738	100.0%	1,876,738	100.0%	1,876,738	100.0%	1,902,422	100.0%	1,902,422	100.0%	1,902,422	100.0%
Cost of services ¹	(724,069)	-38.6%	(1,126,043)	-60.0%	(750,695)	-40.0%	(730,101)	-38.4%	(1,141,453)	-60.0%	(760,969)	-40.0%
Gross Income	1,152,669	61.4%	750,695	40.0%	1,126,043	60.0%	1,172,321	61.6%	760,969	40.0%	1,141,453	60.0%
Sales expenses	(210,137)	-11.2%	(210,137)	-11.2%	(210,137)	-11.2%	(212,092)	-11.1%	(212,092)	-11.1%	(212,092)	-11.1%
Contribution margin	942,532	50.2%	540,558	28.8%	915,906	48.8%	960,229	50.5%	548,877	28.9%	929,361	48.9%
(Decrease) increase in margin			(401,974)	-21.4 p.p	(26,626)	-1.4 p.p			(411,352)	-21.6 p.p	(30,868)	-1.6 p.p.

¹It excludes the provision for incurred events/claims but not reported (PEONA) and technical reserves for claims.

Increase/decrease in contribution margin (Notes 19, 20, 21)

	Company						Consolidated					
	Period ended December 31, 2021		Changes in loss ratio				Period ended December 31, 2021		Changes in loss ratio			
			Equal to 60%		Equal to 40%				Equal to 60%		Equal to 40%	
Sales revenue	1,809,030	100.0%	1,809,030	100.0%	1,809,030	100.0%	1,842,434	100.0%	1,842,434	100.0%	1,842,434	100.0%
Cost of Services	(717,704)	-39.7%	(1,085,418)	-60.0%	(723,612)	-40.0%	(724,314)	-39.3%	(1,105,460)	-60.0%	(736,974)	-40.0%
Gross Income	1,091,326	60.3%	723,612	40.0%	1,085,418	60.0%	1,118,120	60.7%	736,974	40.0%	1,105,460	60.0%
Sales expenses	(188,791)	-10.4%	(188,791)	-10.4%	(188,791)	-10.4%	(191,096)	-10.4%	(191,096)	-10.4%	(191,096)	-10.4%
Contribution margin	902,535	49.9%	534,821	29.6%	896,627	49.6%	927,024	50.3%	545,878	29.6%	914,364	49.6%
(Decrease) increase in margin			(367,714)	-20.2 p.p.	(5,908)	-0.2 p.p.			(381,146)	-20.8 p.p.	(12,660)	-0.8 p.p.

¹It excludes the provision for incurred events/claims but not reported (PEONA) and technical reserves for claims.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

4.3. Strategy risk – market of operation (competition)

The Company operates in a competitive market, competing with operators of health insurance and exclusive dental care, hospital/medical plans, dental care cooperatives and charity entities that offer dental care plans with similar benefits.

Odontoprev sells dental care plans to companies, associations, and individuals through: (i) an internal sales team; (ii) external brokers; (iii) commercial partnerships and alternative distribution channels and (iv) Bradesco.

The factors driving the growth of the dental plan sector are: (i) structural imbalance between the supply and demand of services; (ii) lack of alternatives in the public system; (iii) inclusion of dental care plans in employee benefit programs; (iv) opportunities represented by the increasing interest of new distribution ways, and (v) regulation.

4.4. Legal and regulatory risk – capital

The Company carries out its capital risk management activities based on a centralized model, with the main purpose of meeting the requirements of minimum regulatory capital for its segment, according to the capital requirements defined by ANS, as well as increasing the return on capital to the shareholders. The strategy and model used by Management consider both “regulatory capital” and “economic capital”.

The Company keeps capital levels above the regulatory requirements (Note 13.1).

4.5. Operating risk

The operating risk is the measure of uncertainty that understands the risks related to the internal procedures (loss resulting from inadequacies or failures in internal processes, people and systems).

The Company has a set of standards, processes and organizational structures to manage operating risk, including Internal Audit; departments of the second line of defense; segregation of duties in activities and processes; limitations of authority by levels; logical security in IT systems; communication channels for receiving complaints; business continuity plan; insurance contracted to cover buildings, machinery, furniture, fixtures and facilities, vehicles, loss of profits, D&O civil liability, cybernetic liability for breach of security and privacy; etc.

5. Cash and cash equivalents

	Company		Consolidated	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Cash	10	12	86	96
Cash in transit ¹	10,599	14,649	10,599	14,649
Banks checking account	3,695	167	4,231	723
Interest earning bank deposits (remunerated current account)	511	756	921	954
	14,815	15,584	15,837	16,422

¹Receipts from customers to be transferred by financial institutions, as well as monetary amounts under confirmation.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

6. Interest earning bank deposits (financial assets at fair value through profit or loss and held to maturity)

	Rating	Company		Consolidated	
		December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Fixed income from inv. fund	Current assets	104,614	289,303	127,381	304,474
CETES	Current assets	-	-	8,211	10,666
Fair value through profit or loss		104,614	289,303	135,592	315,140
NTN-B	Current assets	41,074	-	41,074	-
LTN	Current assets	38,435	-	38,435	-
NTN-B	Non-current assets	430,257	286,694	430,257	286,694
NTN-F	Non-current assets	124,384	109,757	124,384	109,757
LTN	Non-current assets	9,652	3,036	9,652	3,036
Held to maturity		643,802	399,487	643,802	399,487
		748,416	688,790	779,394	714,627
	Current assets	184,123	289,303	215,101	315,140
	Non-current assets	564,293	399,487	564,293	399,487
		748,416	688,790	779,394	714,627

Investment funds (FI fixed income): investment fund quotas on Bradesco FI RF Bond and BRAM FI RF Referenced DI Coral which are valued based on the value disclosed by Bradesco Asset Management.

Certificados de la Tesorería de la Federación (CETES): fixed-income public bonds held by Odontored issued by the Mexican government.

National Treasury Notes – Series B (NTN-B): federal public bonds, refer to the assets from managed portfolios, which are managed by Bradesco Asset Management. As of December 31, 2022, the fair value is R\$ 448,616 (R\$ 270,413 as of December 31, 2021).

National Treasury Notes – Series F (NTN-F): federal public bonds, refer to the assets from managed portfolios, which are managed by Bradesco Asset Management. As of December 31, 2022, the fair value is R\$ 110,356 (R\$ 102,638 as of December 31, 2021).

National Treasury Bills (LTN): federal public bonds, refer to the assets from managed portfolios, which are managed by Bradesco Asset Management. As of December 31, 2022, the fair value is R\$ 47,931 (R\$ 3,036 as of December 31, 2021).

	Rating	Investment portfolio per original maturities - Company				Total
		Without maturity	01–180 days	181–360 days	>360 days	
Fixed income from inv. fund	Current assets	104,614	-	-	-	104,614
Fair value through profit or loss		104,614	-	-	-	104,614
NTN-B	Current assets	-	41,074	-	-	41,074
LTN	Current assets	-	-	38,435	-	38,435
NTN-B	Non-current assets	-	-	-	430,257	430,257
NTN-F	Non-current assets	-	-	-	124,384	124,384
LTN	Non-current assets	-	-	-	9,652	9,652
Held to maturity		-	41,074	38,435	564,293	643,802
December 31, 2022		104,614	41,074	38,435	564,293	748,416
December 31, 2021		289,303	-	-	399,487	688,790

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

		Investment portfolio per original maturities - Consolidated					
	Rating	Without maturity	01–180 days	181–360 days	>360 days	Total	
Fixed income from inv. fund	Current assets	127,381	-	-	-	127,381	
CETES	Current assets	-	8,211	-	-	8,211	
Fair value through profit or loss		127,381	8,211	-	-	135,592	
NTN-B	Current assets	-	41,074	-	-	41,074	
LTN	Current assets	-	-	38,435	-	38,435	
NTN-B	Non-current assets	-	-	-	430,257	430,257	
NTN-F	Non-current assets	-	-	-	124,384	124,384	
LTN	Non-current assets	-	-	-	9,652	9,652	
Held to maturity		-	41,074	38,435	564,293	643,802	
December 31, 2022		127,381	49,285	38,435	564,293	779,394	
December 31, 2021		304,474	10,666	-	399,487	714,627	

		Fair value through profit or loss						Amortized cost				
	CDBs	FI ANS	FF fixed income	LFT	FB	Total	NTN-B1	NTN-F	LTN	Total	Total	
December 31, 2020	3,723	-	523,763	132,897	21,882	682,265	16,541	-	-	16,541	698,806	
Rede Dental merger ²	-	886	5,209	-	-	6,095	-	-	-	-	6,095	
Investments	-	-	899,799	-	3,293	903,092	260,797	108,492	3,000	369,289	1,272,381	
(-) Redemptions	(3,751)	(888)	(1,156,054)	(134,768)	(25,382)	(1,320,843)	(15,637)	(4,868)	-	(20,505)	(1,341,348)	
Earnings	28	2	16,586	1,871	207	18,694	24,993	6,133	36	31,126	49,820	
December 31, 2021	-	-	289,303	-	-	289,303	286,694	109,757	3,036	399,487	688,790	
Mogidonto merger ³	-	883	-	-	-	883	-	-	-	-	883	
Investments	-	-	976,885	-	-	976,885	170,954	26,770	40,995	238,719	1,215,604	
(-) Redemptions	-	(934)	(1,186,446)	-	-	(1,187,380)	(21,096)	(22,322)	-	(43,417)	(1,230,797)	
Earnings	-	51	24,872	-	-	24,923	34,779	10,179	4,056	49,013	73,936	
December 31, 2022	-	-	104,614	-	-	104,614	471,331	124,384	48,087	643,802	748,416	

¹Redemptions corresponding to receipt of interest coupon

²Subsidiary merged as of January 04, 2021.

³Subsidiary merged on January 03, 2022.

		Fair value through profit or loss						Amortized cost				
	CDBs	FI ANS	Fixed income from inv. fund	LFT	FB	CETES	Total	NTN-B1	NTN-Fi	LTN	Total	Total
December 31, 2020	3,723	886	533,865	132,897	21,882	8,746	701,999	16,541	-	-	16,541	718,540
Mogidonto consolidation ²	-	761	3,933	-	-	-	4,694	-	-	-	-	4,694
Investments	-	100	975,932	-	3,293	105,103	1,084,428	260,798	108,492	3,000	372,290	1,456,718
(-) Redemptions	(3,751)	(888)	(1,227,427)	(134,768)	(25,382)	(103,619)	(1,495,835)	(15,637)	(4,868)	-	(20,505)	(1,516,340)
Earnings	28	24	17,288	1,871	207	436	19,854	24,992	6,133	36	31,161	51,015
December 31, 2021	-	883	303,591	-	-	10,666	315,140	286,694	109,757	3,036	399,487	714,627
Investments	-	-	1,070,029	-	-	74,491	1,144,520	170,954	26,770	40,995	238,719	1,383,239
(-) Redemptions	-	(934)	(1,273,775)	-	-	(77,614)	(1,352,323)	(21,096)	(22,322)	-	(43,418)	(1,395,741)
Earnings	-	51	27,536	-	-	668	28,255	34,779	10,179	4,056	49,014	77,269
December 31, 2022	-	-	127,381	-	-	8,211	135,592	471,331	124,384	48,087	643,802	779,394

¹Redemptions corresponding to receipt of interest coupon.

²Subsidiary merged as of January 03, 2022.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Sufficiency of guaranteeing interest earning bank deposits (according to RN 393/2015 amended by ANS RN 531/2022)

Technical reserves	Rating	Company	
		December 31, 2022	December 31, 2021
PESL (over 30/60 days)	Current liabilities	12,814	13,494
PEONA	Current liabilities	101,116	98,534
Link required by ANS		113,930	112,028
PESL (total)	Current liabilities	68,197	54,969
PEONA	Current liabilities	101,116	98,534
Guarantee required by ANS		169,313	153,503
Relationship and guarantee of technical reserves			
NTN-B	Current assets	4,952	-
NTN-B	Non-current assets	112,995	113,727
NTN-F	Non-current assets	53,774	41,862
Pledged financial investments		171,721	155,589
NTN-B	Non-current assets	17,474	16,843
NTN-F	Non-current assets	6,799	6,838
Interest earning bank deposits - guarantors		195,994	179,270

7. Receivables from operations with healthcare plans (clients)

	Company		Consolidated	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Cash considerations/premiums receivable (bills)	184,042	160,514	178,261	161,419
Provision for credit losses (PPSC)	(23,466)	(24,447)	(23,253)	(24,797)
Cash considerations/Premiums receivable	160,576	136,067	155,008	136,622
Participation of beneficiaries in indemnifying events/claims (debit notes)	1,313	811	1,313	811
Provision for credit losses (PPSC)	-	(2)	-	(2)
Participation of beneficiaries in indemnifying events/claims	1,313	809	1,313	809
Healthcare plan operators (operators' bills)	9,394	8,455	5,191	8,455
Health care plan operators	9,394	8,455	5,191	8,455
Other credits with health care plans (insurance)	-	-	13,055	11,307
Receivables from operations with healthcare plans (clients)	171,283	145,331	174,567	157,193
Invoices, debit notes, operators and insurance	194,749	169,780	197,820	181,993
Provision for credit losses	(23,466)	(24,449)	(23,253)	(24,800)
Receivables from operations with healthcare plans (clients)¹	171,283	145,331	174,567	157,193

¹Amounts receivable at the Company include the consideration and management fee for post-payment products, as provided for in ANS regulations.

Receivables from operations with health care plans by aging list

Maturity	Company				Consolidated			
	Invoices, debit notes and operators	Provision for credit losses	December 31, 2022	December 31, 2021	Invoices, debit notes, operators and insurance	Provision for credit losses	December 31, 2022	December 31, 2021
Falling due	130,341	(208)	130,133	119,400	133,978	(204)	133,774	131,083
Overdue (days):								
up to 30	34,985	(2,898)	32,087	18,757	34,584	(2,852)	31,732	18,884
31-60	11,230	(3,695)	7,535	6,366	11,187	(3,566)	7,621	6,412
61-90	4,665	(3,711)	954	609	4,620	(3,662)	958	614
>91	13,528	(12,954)	574	199	13,451	(12,969)	482	200
	194,749	(23,466)	171,283	145,331	197,820	(23,253)	174,567	157,193

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Changes in provision for losses on loans and clients			
	Company		Consolidated	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Invoices	184,042	160,514	178,261	161,419
Debit Notes	1,313	811	1,313	811
Invoices - operators	9,394	8,455	5,191	8,455
Insurance	-	-	13,055	11,308
	194,749	169,780	197,820	181,993
PPSC: opening balance	(24,449)	(30,557)	(24,798)	(30,738)
PPSC: provisions (reversals) formed	(47,477)	(48,663)	(47,738)	(48,920)
PPSC: actual losses	48,460	54,771	49,283	54,858
	(23,466)	(24,449)	(23,253)	(24,800)
Receivables from operations with healthcare plans (clients)	171,283	145,331	174,567	157,193
Advances from clients	527	-	527	(1,703)
Clients, net	171,810	145,331	175,094	155,490

8. Tax and social security credits (recoverable taxes)

	Company		Consolidated	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
INSS	143	143	143	152
IRPJ	14,574	8,059	16,363	9,921
CSLL	2,373	1,090	4,191	3,170
IRRF	114	321	1,058	1,600
PIS and COFINS	162	72	2,258	2,169
ISS	1,191	1,565	1,191	1,568
Other	-	-	711	1,332
	18,557	11,250	25,915	19,912
Current assets	1,610	11,250	8,968	19,912
Non-current assets	16,947	-	16,947	-
	18,557	11,250	25,915	19,912

Corporate income tax (IRPJ) and social contribution (CSLL): Corporate income tax (IRPJ) balance composed of advances from the current and previous years, and social contribution (CSLL) balance composed of credits from previous years, both arising from technological innovation, subject to approval by the MCTI (Ministry of Science, Technology and Innovation).

ISS: Credits on undue deductions of ISS, in the municipalities of Rio de Janeiro and Curitiba, by clients who require the registration of Odontoprev with the Register of Service Providers of Other Municipalities (CPOM). This retention is considered unconstitutional by the ruling of the Federal Supreme Court. In this sense, the Company has a lawsuit against this requirement of registration with the CPOM, as well as to request the values retained from its clients.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated) December 31, 2022 and 2021 (Amounts expressed in thousands of Reais, unless otherwise indicated)

9. Long-term assets

9.1. Deferred IRPJ/CSLL – assets and liabilities

	Rating	Realization estimate	Note	Company			Consolidated				
				December 31, 2021	Formation	Realized	December 31, 2022	December 31, 2021	Formation	Realized	December 31, 2022
Timing differences											
Provision for credit losses	Assets	Up to 12 months	7	8,312	-	(334)	7,978	8,370	-	(329)	8,041
Provisions for lawsuits (contingencies) ¹	Assets	> 12 months	16,1	22,037	-	(10,510)	11,527	22,602	-	(10,579)	12,023
Sundry provisions	Assets	Up to 12 months	15	8,217	-	(769)	7,448	8,487	-	(917)	7,570
Long-term incentive program (ILP)	Assets	Up to 12 months	-	8,093	2,790	-	10,883	9,467	2,893	-	12,360
Other	Assets	Up to 12 months	-	9,235	2,189	-	11,424	10,312	2,141	-	12,453
Deferred IRPJ/CSLL (Assets)				55,894	4,979	(11,613)	49,260	59,238	5,034	(11,825)	52,447
Amortization of goodwill	Liabilities	-	-	(31,132)	(12,097)	-	(43,229)	(31,141)	(12,097)	-	(43,229)
Other	Liabilities	-	-	-	-	-	-	-	(5)	-	(5)
Deferred IRPJ/CSLL (Liabilities)				(31,132)	(12,097)	-	(43,229)	(31,141)	(12,102)	9	(43,234)
Deferred IRPJ/CSLL				24,762	(7,118)	(11,613)	6,031	28,097	(7,068)	(11,816)	9,213
Deferred income tax (IRPJ)				18,207	(8,436)	(8,539)	1,232	20,660	(5,198)	(8,688)	6,774
Deferred social contribution (CSLL)				6,555	1,318	(3,074)	4,799	7,437	(1,870)	(3,128)	2,439
Deferred IRPJ/CSLL				24,762	(7,118)	(11,613)	6,031	28,097	(7,068)	(11,816)	9,213

9.2. Judicial and tax deposits

	Company		Consolidated	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Tax	19,631	15,678	21,520	18,527
ISS ¹	17,451	14,339	17,451	14,339
Other	2,180	1,339	4,069	4,188
Social security and labor	1,088	3,386	1,521	3,795
Civil	3,518	2,963	3,518	3,044
	24,237	22,027	26,559	25,366

¹From the merged company Odonto System, the full amount of the Service Tax – ISS was deposited in court without deducting the events from the calculation basis (object of the lawsuit). Amount fully provisioned in non-current liabilities under "Taxes and social security charges payable".

9.3. Other credits receivable

Provision for potential risks determined in the review of accounting, tax and labor procedures of acquired companies (Note 12.1), which has a corresponding entry to "other payables" (Note 16.3). By means of an agreement, the former owners of the acquired companies guarantee the reimbursement of any payments the Company and its subsidiaries are required to make.

	Company		Consolidated	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Papaiz Group	-	-	-	1,323
Odonto System ¹	12,257	13,889	12,257	13,889
Mogidonto	6,166	-	6,166	7,126
Boutique Dental	-	-	-	4,665
Other	-	-	2B4	294
	18,423	13,889	18,707	27,297

¹Amounts guaranteed by guarantee insurance and surety letter.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

10. Investments

Information as of December 31, 2022	Interest in jointly-controlled subsidiaries - Jointly-controlled subsidiary						Company
	Mogidonto1	Odontored	Clidec	Odontoprev	Total	Brasilental	Total investments
				Serviços			
Capital	-	6,935	12,790	9,700	-	9,500	-
Quotas/Shares	-	6,935	12,790	9,700	-	380,000	-
Interest (%)	-	60.0	99.9	99.9	-	25.0	-
Total assets	-	28,289	39,249	45,136	-	50,979	-
Liabilities	-	28,289	33,519	32,232	-	23,109	-
Shareholders' equity	-	6,943	31,697	31,484	-	28,644	-
Net revenue	-	18,679	29,047	61,158	-	108,156	-
Costs and expenditures	-	22,028	20,305	48,254	-	65,591	-
Taxes and interests	-	-	3,013	-	-	14,695	-
Income (loss) for the year	-	(3,349)	5,729	12,904	-	27,870	-
December 31, 2021	4,634	5,743	25,655	18,884	54,916	5,363	60,279
Mogidonto merger ¹	(4,634)	-	-	-	(4,634)	-	(4,634)
Acquisition of equity interest	-	3,968	-	-	3,968	-	3,968
Stock option in subsidiaries	-	-	304	50	354	-	354
Dividends	-	-	-	-	-	(5,169)	(5,169)
Revenue (expense) in equity in net income of subsidiaries	-	(3,259)	5,733	12,906	15,380	6,967	22,347
Other comprehensive income	-	491	5	(356)	140	-	140
December 31, 2022	-	6,943	31,697	31,484	70,124	7,161	77,285

¹Subsidiary merged as of January 03, 2022.

	Consolidated			
	Investments		Equity in net income of subsidiaries	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Investments/equity method - Company	77,285	60,279	22,347	12,233
Eliminations for the consolidated:	(70,124)	(54,916)	(15,380)	(6,538)
Subsidiaries (regulated entities)	(6,943)	(10,377)	3,259	(2,495)
Subsidiaries (other companies)	(63,181)	(44,539)	(18,639)	(4,043)
Interest in jointly-controlled subsidiaries - other companies	8,904	7,841	618	650
Interests in other companies	1,795	1,289	(976)	214
	17,860	14,493	6,609	6,559

11. Property, plant and equipment

	Changes in property, plant and equipment - Company										
	December 31, 2021	Acquisitions	Mogidonto merger ¹	Write-offs	Transfers	Depreciations / Amortizations	December 31, 2022	Cost of acquisition	Depreciations / Amortizations	Book balance, net	Annual depreciation rate (%)
	IT equipment	8,462	1,316	18	(993)	(306)	(2,468)	6,029	26,095	(20,066)	6,029
Vehicles	941	816	-	(288)	-	(221)	1,248	1,838	(590)	1,248	20
Facilities	780	389	23	(544)	(22)	(260)	366	507	(141)	366	10
Machinery and Equip.	377	318	90	(310)	32	(83)	424	1,703	(1,279)	424	10
Furniture and fixtures	1,106	281	9	(401)	76	(318)	753	3,306	(2,553)	753	10
Communication equipment	461	134	3	(277)	(12)	(172)	137	743	(606)	137	10
Dental equipment	38	-	-	-	55	(5)	88	519	(431)	88	10
Property, plant and equipment for use	12,165	3,254	143	(2,813)	(177)	(3,527)	9,045	34,711	(25,666)	9,045	
Other property, plant and equipment limit	6,510	3,545	-	(2,056)	(68)	(2,188)	5,743	15,360	(9,617)	5,743	20
Property, plant and equipment	18,675	6,799	143	(4,869)	(245)	(5,715)	14,788	50,071	(35,283)	14,788	
Right-of-use (CPC 06 (R2)/IFRS 16) ²	31,416	1,079	-	(17,172)	-	(2,557)	12,766	15,342	(2,576)	12,766	
Property, plant and equipment	50,091	7,878	143	(22,041)	(245)	(8,272)	27,554	65,413	(37,859)	27,554	

¹Subsidiary merged as of January 03, 2022. (Note 1).

²Depreciation calculated according to the duration of the lease contract.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Changes in Property, Plant and Equipment - Consolidated										
	December 31, 2021	Acquisitions	Write-offs	Transfers	Depreciations / Amortizations	December 31, 2022	Cost of acquisition	Depreciations / Amortizations	Book balance, net	Annual depreciation rate (%)
IT equipment	9,090	1,353	(1,000)	(108)	(2,722)	6,613	28,118	(21,505)	6,613	20
Vehicles	1,014	816	(288)	-	(263)	1,279	1,990	(711)	1,279	20
Facilities	1,079	452	(662)	(83)	(358)	428	699	(271)	428	10
Machinery and Equip.	667	627	(323)	112	(109)	974	2,737	(1,763)	974	10
Furniture and fixtures	1,866	337	(508)	131	(498)	1,328	4,591	(3,263)	1,328	10
Communication equipment	509	134	(296)	(17)	(173)	157	765	(608)	157	10
Dental equipment	1,170	43	(70)	(46)	(196)	901	3,087	(2,186)	901	10
Buildings	6,500	-	-	-	(289)	6,210	7,221	(1,011)	6,210	-
Total for own use	21,895	3,762	(3,147)	(11)	(4,608)	17,890	49,208	(31,318)	17,890	
Other property, plant, and equipment (improvements)	7,622	4,634	(2,560)	(68)	(2,516)	7,112	19,066	(11,954)	7,112	20
Total other property, plant and equipment	29,517	8,396	(5,707)	(79)	(7,124)	25,002	68,274	(43,272)	25,002	
Right-of-use (CPC 06 (R2)/IFRS 16) ¹	40,718	5,124	(21,041)	-	(5,060)	19,741	25,897	(6,156)	19,741	-
Total property, plant and equipment	70,235	13,520	(26,748)	(79)	(12,184)	44,743	94,171	(49,428)	44,743	

¹Depreciation calculated according to the duration of the lease contract.

12. Intangible assets

12.1. Goodwill on the acquisition of investments

	Historical data related to acquisition and/or approval						December 31, 2022			December 31, 2021
	Date	Total amount	Equity value	Strategic focus	CGU	Merger date	Goodwill	Amortization / baixa ¹	Net goodwill	Net goodwill
Bradesco Dental	10/18/2009	723,392	313,752	Corporate and Individual	Bradesco	07/01/2010	409,640	-	409,640	409,640
Biodent	06/19/2008	2,837	98	Premium segment	Odontoprev ³	12/01/2008	2,739	(319)	2,420	2,420
Care Pus	06/19/2008	13,113	(230)	Premium segment	Odontoprev ³	12/01/2008	13,343	(1,563)	11,780	11,780
SRJSPE	06/26/2008	13,720	(130)	Premium segment	Odontoprev ³	12/01/2008	13,850	(1,616)	12,234	12,234
Rede Dental ¹	10/08/2007	7,584	(119)	Regionalization	Odontoprev ³	01/04/2021	7,703	(1,544)	6,159	6,159
OdontoSeny ²	02/27/2009	30,841	10,025	Regionalization	Odontoprev ³	12/01/2009	20,816	-	20,816	20,816
Prontodente	12/22/2008	5,445	(235)	Medium and large-sized enterprises	Odontoprev ³	12/01/2009	5,680	-	5,680	5,680
Sepao	10/24/2008	9,203	82	Medium and large-sized enterprises	Odontoprev ³	12/01/2009	9,120	(303)	8,817	8,817
DentalCorp	02/09/2007	25,244	386	Small and medium-sized companies	Odontoprev ³	03/03/2008	24,858	(9,529)	15,329	15,329
Odonto System	08/07/2018	203,084	4,668	Portfolio complementarity	Odonto System	01/02/2019	145,793	-	145,793	145,793
Mogidonto ⁵	07/01/2021	19,973	3,693	Medium and large-sized enterprises	Mogidonto	01/03/2022	16,280	-	16,280	16,280
Company		1,054,436	331,990				669,822	(14,874)	654,948	654,948
Easy	07/08/2008	3,100	456	Verticalization	-	Not merged	2,644	(264)	2,380	2,380
Papaiz Group	01/31/2013	5,487	780	Verticalization	-	Not merged	6,008	-	6,008	6,008
Boutique Dental	07/01/2021	1,247	593	Verticalization	-	Not merged	654	-	654	654
Consolidated		1,064,270	333,819				679,128	(15,138)	663,990	663,990

¹Accumulated straight-line amortization until December 31, 2008, after this date impairment tests are performed.

²It includes Adcon, merged on May 01, 2014.

³Equivalent to the Company's total income less the CGUs Bradesco, Odonto System, and Mogidonto. This grouping is due to the strategic focus of these acquisitions being closely related to Odontoprev's commercial and retention activities, as well as the identification of independent cash inflow. In 2022, the CGUs Care Pus, Rede Dental and Odontoserv were grouped into the CGU of Odontoprev.

The Company evaluates its recoverability through impairment tests (note 2.5.1 and (i)) for goodwill from acquisitions of investments allocated to cash generating units (CGUs).

The last impairment test, where the approach of income was applied through discounted cash flows methodology (value in use) based on nature of each Cash Generating Unit (CGU), on existence of financial and operating control, history and availability of financial projections.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Assumptions On November 30, 2022

Determination period:	Five years and one month from December 01, 2022 to December 31, 2027 and perpetuity
Growth rate in perpetuity:	3.3 p.a. based on the long-term inflation rate (IPCA)
Projection currency:	Nominal R\$, considering the inflationary effect
Discount rate:	14.1% according to CAPM ¹ methodology
Specific assumptions:	(i) financial and management statements of CGU and Odontoprev; (ii) management information that includes the group's budget

Macroeconomic assumptions:	Description	2022P	2023P	2024P	2025P	2026P
	GDP change	2.80%	0.70%	1.70%	1.90%	2.00%
	IGP-M	5.90%	5.10%	4.20%	3.90%	3.80%
	Inflation - IPCA	5.50%	4.50%	3.60%	3.40%	3.30%

¹CAPM - Capital Asset Pricing Model

The conclusion was that the value in use obtained by applying such assumptions is higher than the book value; therefore, there no indications of impairment.

12.2. Intangible assets

	Company				Consolidated			
	Goodwill in investment acquisitions	Development of systems and software use licenses	Allocated intangible assets	Intangible assets	Goodwill in investment acquisitions	Development of systems and software use licenses	Allocated intangible assets	Intangible assets
December 31, 2021	654,948	85,916	33,492	774,356	663,990	88,356	33,953	786,299
Additions	-	62,637	-	62,637	-	62,990	-	62,990
Mogidonto merger ¹	-	2	-	2	-	-	-	-
Write-offs	-	(1,887)	-	(1,887)	-	(1,887)	-	(1,887)
Transfers	-	-	-	-	-	21	(21)	-
Amortizations	-	(21,523)	(2,539)	(24,062)	-	(22,201)	(2,568)	(24,769)
December 31, 2022	654,948	125,145	30,953	811,046	663,990	127,279	31,364	822,633
Cost	669,822	229,694	69,514	969,030	679,128	235,479	69,953	984,560
Accumulated amortizations	(14,874)	(104,549)	(38,561)	(157,984)	(15,138)	(108,200)	(38,589)	(161,927)
Book balance, net	654,948	125,145	30,953	811,046	663,990	127,279	31,364	822,633
Amortization period		5 years	Useful life - appraisal report			5 years	Useful life - appraisal report	

¹Subsidiary merged as of January 03, 2022.

13. Minimum capital and technical reserves for health care operations

ANS establishes the rules for recognizing technical reserves and criteria for maintaining minimum shareholders' equity in accordance with NR 526/2022.

RN 526/2022 also provides for the adoption of a regulatory capital model based on risks, which is mandatory for all operators as of 2023, however, early adoption is permitted. In May 2020, the Company filed an instrument of commitment (early adoption).

Due to the option for the early use of the standard capital model based on risks under the terms of Article 14 of RN 526/2022, the determination of the regulatory capital must take the highest of the following amounts into consideration: (i) base capital; (ii) the fixed solvency margin of 75%, and (iii) risk-based capital (includes the following risks on December 31, 2022: subscription, credit, legal and operational).

13.1. Minimum capital

(a) The base capital (BC) represents the minimum value of shareholders' equity, calculated by multiplying the K factor by the reference equity.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

(b) The solvency margin (SM) corresponds to the amount of adjusted shareholders' equity (AE) enough (S) to cover the higher of 0.20 times the sum of the last 12 months premium or 0.33 times the annual average of the last 36 months of indemnifiable claims, net.

(c) Underwriting risk is the uncertainty measure related to an adverse economic position that goes against the operator's expectation at the time of the preparation of its underwriting policy regarding the uncertainties existing in the estimate of the technical reserves and provisions related to pricing.

(d) The credit risk is the measure of uncertainty related to the probability of the counterparty of an operation, or of an issuer of debt, not honoring, total or partially, their financial commitments, or having changed their classification of credit risk.

(e) The operational risk is the measure of uncertainty that understands the risks related to the internal procedures (loss resulting from inadequacies or failures in internal processes, people and systems).

(f) The legal risk is a measure of uncertainty regarding the lack of a comprehensive legal foundation; it is the risk of non-compliance with laws, rules, regulations, agreements, current practices or ethical standards applicable, also considering the risk that the nature of the product/service provided can make the operator particularly vulnerable to litigation.

(g) Market risk is the measure of uncertainty related to exposure to losses arising from the volatility of asset prices, such as stock prices, interest rates, exchange rates, commodity prices and real estate prices.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

	Company: calculation of PMA, PLA, MS and S	
	December 31, 2022	December 31, 2021
Reference capital	10,883	9,727
(x) K factor ¹	3.23%	3.23%
Adjusted minimum shareholders' equity (PMA)	352	314
Book value of shareholders' equity	1,184,159	1,115,804
Ownership interest in regulated entities	(7,161)	(9,997)
Deferred acquisition costs	(34,418)	(30,292)
Prepaid expenses	(4,158)	(4,527)
Intangible assets	(817,708)	(774,356)
Adjusted shareholders' equity (PLA)	320,714	296,632
(-) Effects of CPC 06 (R2)/IFRS 16 ⁴	2,886	1,552
Adjusted shareholders' equity, excluding CPC 06(R2)/IFRS 16 (ANS ASE)	323,600	298,184
(A) 0.20 times the sum of the considerations - last 12 months	390,058	370,071
(B) 0.33 times the average of events - last 36 months	217,710	224,025
Total solvency margin (MS) = the greater between (A) and (B)²	390,058	370,071
MS required ³ (%)	75.000%	75.000%
MS required ³ (R\$)	292,544	277,553
Required sufficiency (ANS ASE - MS required)	31,056	20,631
Risk-based capital (CBR)⁵	232,286	227,805

¹K Factor corresponds to the classification: group dentistry, tertiary segment and region 1 according to appendix RN 526/2022.

²Total solvency margin must be constituted until December 31, 2022, according to RN 526/2022.

³75% fixed due to early adoption of Normative Resolution 451/2020, revoked by Normative Resolution 526/2022.

⁴Refers to the effects, in the income, of CPC 06(R2)/IFRS 16 - Leases, not approved by ANS until December 31, 2021.

⁵CBR December 31, 2022 Normative Resolution 526 = underwriting risk (CRS) + credit (CRC) + operational and legal (CRO); December 31, 2021 (RN 451, revoked by RN 526) = underwriting risk (CRS). On December 31, 2022, considering the CRM approved by Normative Resolution 569 of December 19, 2022, the CBR would be 318,369.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

13.2. Changes in technical reserves and deferred acquisition costs

According to CPC 11/IFRS 4, we highlight the changes in the technical reserves for health care operations related to events (insurance liabilities) and deferred sales expenses:

	Company			Consolidated			Company and Consolidated
	PPCNG	PBSL	PBONA	PPCNG	PBSL	PBONA	DCD1
December 31, 2020	181,332	71,148	91,102	181,389	71,178	91,586	26,152
Rede Dental merger ²	57	30	484	-	-	-	-
Mogidonto merger ⁴	-	-	-	265	419	267	-
Net indemnifiable events	-	695,884	-	-	688,291	-	-
Events paid	-	(712,093)	-	-	(704,461)	-	-
PEONA change	-	-	6,948	-	-	6,921	-
Unearned considerations	1,911,203	-	-	1,918,311	-	-	-
Considerations appropriated to the income (loss)	(1,891,478)	-	-	(1,898,595)	-	-	-
Deferred sales expenses	-	-	-	-	-	-	(24,411)
Appropriated trading expenses	-	-	-	-	-	-	28,551
Insurance appropriated to income (loss)	-	-	-	-	-	-	24,507
Insurance ²	-	-	-	-	-	-	(27,361)
Claims incurred	-	-	-	-	-	-	4,926
Claims paid ²	-	-	-	-	-	-	(4,697)
December 31, 2021	201,114	54,969	98,534	201,370	55,427	98,774	30,292
Reclassification of post-payment plans ⁵	-	-	-	-	(4,967)	-	-
Net indemnifiable events	-	687,436	-	-	675,268	-	-
Events paid	-	(674,667)	-	-	(662,498)	-	-
Mogidonto merger ⁴	256	459	240	-	-	-	-
PEONA change	-	-	2,342	-	-	2,342	-
Unearned considerations	1,997,071	-	-	1,996,997	-	-	-
Considerations appropriated to the income (loss)	(1,967,571)	-	-	(1,967,497)	-	-	-
Deferred sales expenses	-	-	-	-	-	-	(24,927)
Appropriated trading expenses	-	-	-	-	-	-	29,053
Insurance appropriated to income (loss)	-	-	-	-	-	-	18,679
Insurance ²	-	-	-	-	-	-	(16,999)
Claims incurred	-	-	-	-	-	-	(5,769)
Claims paid ²	-	-	-	-	-	-	6,062
December 31, 2022	230,870	68,197	101,116	230,870	63,230	101,116	34,418

¹Assets directly related to insurance contracts for the Company and Consolidated.

²Control of Odontored (Note 1).

³Subsidiary merged on January 04, 2021.

⁴Acquisition in July 2021 and merged on January 03, 2022.

⁵On September 29, 2021, the National Supplementary Health Agency (ANS) issued Normative Resolution 528, which came into force on June 1, 2022. The aforementioned standard changed the recording of the value of indemnifiable events charged to the contracting party of the operations in the post-established price modality to adapt to CPC 47 - Revenue from Contracts with Customers, as it is a reimbursement by the contracting party of the cost of assistance services provided.

14. Taxes payable (tax liabilities)

	Company		Consolidated	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Income tax and social contribution payable	8,458	1,018	8,944	1,468
IRPJ	6,065	788	6,436	1,107
CSLL	2,393	230	2,508	361
Other federal tax liabilities	14,403	12,522	16,925	15,366
COFINS	4,716	4,262	5,008	4,557
PIS	766	693	830	755
PIS, COFINS and CSLL (PCC)	1,309	1,278	1,339	1,314
IRRF	7,142	5,165	7,516	5,939
IVA ¹	-	-	1,735	1,652
ANS rate	-	603	-	603
Installment payment of taxes ²	461	515	461	515
Other	9	6	36	31
State tax liabilities	-	-	105	61
Municipal tax liabilities	9,628	9,357	9,818	9,684
	32,489	22,897	35,792	26,579

¹Value Added Tax from subsidiary Odontored.

²Installments from Odonto System (note 16.2) merged on January 2, 2019.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

15. Other accounts payable

	Company		Consolidated	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Sundry provisions	22,484	24,167	25,019	24,830
Commissions	4,975	4,032	4,975	4,032
IT support and service	1,280	1,240	1,280	1,249
Telecom	326	309	326	309
Services	1,790	2,145	1,940	2,726
Traveling	-	-	-	49
Indemnifiable events	-	6,188	-	6,188
Free choice ¹	13,685	9,900	13,685	9,900
Marketing actions	371	329	2,756	351
Insurance	57	24	57	26
National Social Security Institute - INSS contribution return²	19,036	17,913	19,036	17,913
Loans to be identified³	15,541	7,031	15,623	7,031
Unearned revenue (CPC 47/IFRS 15)	-	-	69	82
Other	301	460	6,418	4,711
	57,362	49,571	66,165	54,567

¹Provisions for individual plans with free choice of professionals along the banking channel (note 19).

²Refers to amounts to be reimbursed to customers due to the success obtained in the National Social Security Institute – INSS lawsuit.

³Correspond to amounts received from customers still unidentified.

16. Non-current

16.1. Provisions for lawsuits

Changes	Company						December 31, 2021
	December 31, 2022						
	TPS1	Tax Other	ANS3	Civil Other	Social security and labor	Total	
Opening balance	42,912	45	18,070	1,745	2,020	64,792	46,777
Mogidonto merger ²	-	1,509	-	-	-	1,509	128
Formation	-	504	23,305	5,940	1,661	31,410	27,763
Write-offs (payments/reversals)	(38,831)	(605)	(15,842)	(5,121)	(2,330)	(62,729)	(11,633)
Inflation adjustment	(4,081)	2	3,043	73	18	(945)	1,757
Provision	-	1,455	28,576	2,637	1,369	34,037	64,792
Number of lawsuits						903	778

Number of lawsuits

¹ Corresponds to the provision for payment of TPS as described in item (a) (i).

² Subsidiary merged as of January 03, 2022.

³This is a Tax Assessment Notice drawn up by the ANS whose purpose is the non-payment of reimbursement for treatments performed at free choice by beneficiaries linked to certain products, mapped and monitored internally.

Changes	Consolidated						December 31, 2021
	December 31, 2022						
	TPS1	Tax Other	ANS3	Civil Other	Social security and labor	Total	
Opening balance	42,911	2,712	18,070	1,745	2,419	67,857	48,499
Mogidonto consolidation ²	-	-	-	-	-	-	1,333
Formation	-	504	23,305	5,940	1,670	31,419	27,938
Write-offs (payments/reversals)	(38,831)	(605)	(15,842)	(5,120)	(2,539)	(62,937)	(11,682)
Inflation adjustment	(4,080)	2	3,042	73	28	(935)	1,769
Provision	-	2,613	28,575	2,638	1,578	35,404	67,857
Number of lawsuits						916	807

Number of lawsuits

¹ Corresponds to the provision for payment of TPS as described in item (a) (i).

² Subsidiary acquired on July 01, 2021.

³This is a Tax Assessment Notice drawn up by the ANS whose purpose is the non-payment of reimbursement for treatments performed at free choice by beneficiaries linked to certain products, mapped and monitored internally.

As of December 31, 2022, the amounts related to possible losses not provided for in the Company and its Subsidiaries totaled (i) R\$ 5,587 - 21 labor claims; (ii) R\$ 49,442 - 1,372 civil lawsuits; and (iii) R\$ 48,806 - 35 tax claims (As of December 31, 2021, the amounts totaled (i) R\$ 10,348 - 50 labor claims; (ii) R\$ 83,469 - 1,737 civil claims and; (iii) R\$ 22,940 – 30 tax claims).

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

(a) Tax

(i) Private Health Insurance Regulatory Tax per healthcare plan (TPS)

Coupled with a lawsuit distributed on August 16, 2017, the Company and the merged company Rede Dental filed a petition to waive the mandatory requirement of the Regulatory tax per health care plan (“TPS”), authorized by article 20, item I, of Law 9961/2000, as well as reimbursement of amounts paid in the last five years. Once the share was distributed, the urgency protection (injunction) was deferred determining the suspension of the enforceability of the TPS and on May 7, 2018, occurs the favorable judgment to declare the tax not to be applicable, thus sentencing ANS to reimburse the amounts paid since August 16, 2012 (considering the period of 5 years prior to the distribution of the process, which occurred on August 16, 2017).

The ANS filed an Appeal. However, the judges unanimously voted for the complete dismissal of the appeal, with the subpoena of the parties on February 3, 2022. The Favorable decision became final and unappealable on April 4, 2022.

Following the final and unappealable decision favorable to the Company, on July 27, 2022, the respective compliance with the decision occurred, in which calculations were presented in the amount of R\$ 42,375 for refund purposes, at which time ANS agreed with the calculations presented, but challenged the attorney's fees.

The recognition of the asset will be accounted for as soon as the operational procedures for recording the court-ordered debt payment is completed, at which time the credit will be liquid and certain.

(ii) COFINS

The subsidiary Clidec filed a lawsuit requesting to pay COFINS as established by Complementary Law LC7/1970 rather than in accordance with Law 9718/98, and to offset the difference in amounts paid at the rate of 3% against social contribution. The Company was partially successful since the increase in the COFINS calculation basis was determined unconstitutional. Clidec awaits the granting of its claim for offsetting amounts due, as a result of the partially valid decision. The amount involved and provisioned is R\$ 1,158. The likelihood of loss in the current judicial dispute is possible.

(b) Social security and labor

(i) INSS

The merged company Rede Dental also challenged in court the payment of the social security contribution levied on remunerations paid to accredited dentists and the final and unappealable decision handed down on September 12, 2019 was favorable to the company. The company is currently offsetting the credits related to the periods prior to the date the lawsuit was filed, but this offset has not yet been confirmed.

(ii) Other

The Company and its subsidiaries are parties to several labor lawsuits, most of them relating to: (i) recognition of employment relationship; (ii) equal pay; (iii) overtime; (iv) union classification; and (v) indemnities.

(c) Civil

The Company and its subsidiaries are parties to civil lawsuits, mainly involving requests for indemnification for material damages and pain and suffering.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

(d) Tax assessment notices on stock options

On August 31, 2015, tax authorities issued tax assessment notices summarized below, claiming that the Company compensated Managers and Employees who had joined the stock option programs and had exercised that option in calendar years 2010, 2011 and 2012.

(i) Tax assessment notices related to social security contributions for calendar years 2010, 2011 and 2012, plus interest late-payment interest and tax assessment fine in the restated amounts on December 31, 2022 of R\$ 33,443 (company's contribution and GILRAT/SAT) and R\$ 5,399 (third parties). The challenge presented was judged by the 9th Panel of DRJ/Ribeirão Preto – São Paulo, partially accepting the appeal to recognize the compensatory nature. The tax credit recorded was maintained, excluding the portion of the benefit corresponding to the shares subject to calculation basis lock-up. Both parties appealed to the Administrative Board of Tax Appeals (CARF). In October 2019, the Company was notified of the decision on the appeal, which was unfavorable and revises the previous decision, including to reinstate the previously won lockup portion. Also in October 2019, the Company filed a Bill of Review, which was not accepted by the appeal panel and Company became aware of this decision on January 17, 2020. The company currently awaits the inclusion of the Special Appeal for judgment in the agenda. The probability judged by Management, based on the representation of its legal advisors, is assessed as a possible loss.

(ii) Isolated fine resulting from alleged non-withholding of Withholding Income Tax (IRRF) related to calendar years 2010, 2011 and 2012, in the total amount of R\$ 22,044, restated up to December 31, 2022. The challenge presented was judged by the 3rd Panel of DRJ/Ribeirão Preto – São Paulo, partially accepting the appeal to recognize the compensatory nature. The tax credit recorded was maintained, excluding the portion of the benefit corresponding to the shares subject to calculation basis lock-up. Both parties appealed to the Administrative Board of Tax Appeals (CARF). In October 2019, the Company was notified of the decision on the appeal, which was unfavorable and revises the previous decision, including to reinstate the previously won lockup portion. Also in October 2019, the Company filed a Bill of Review, which was not accepted, so Odontoprev filed a special appeal with CARF in January 2020.

In December 2021, the Higher Chamber of Tax Appeals (CSRF) partially heard the Special Appeal filed and dismissed the known part. In February 2022, Motions for Clarification were filed and rejected. Thus, the lawsuit received a final and unappealable unfavorable decision at the administrative level. On February 13, 2023, the Company filed annulment suit 1012050-55.2023.4.01.3400, in progress before the 4th Court of the Judiciary Branch of the Federal District (SJDF), with presentation of a guarantee insurance, whose probability assessed by Management, based on the representation of its legal advisors, is evaluated as a possible loss, due to the jurisprudence on the matter.

The Company, in compliance with decision made in Board of Directors' Meeting held on March 28, 2017, contracted a court guarantee insurance to guarantee and support obligations of lawsuits of the Company and of beneficiaries of the stock option plan approved in a Shareholders' Meeting (which have or will have seized assets or that are required for court discussion), as a result of legal and administrative procedures started by tax authorities as a result of exercise of options by said beneficiaries.

16.2. Installment payment of taxes and contributions

	Company and Consolidated	
	December 31, 2022	December 31, 2021
Social Security	405	663
Federal debts	489	852
Non-current liabilities	894	1,515
Social Security	194	215
Federal debts	267	300
Current liabilities (note 14)	461	515

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

Installments of debts referring to different federal taxes and social security contributions of the subsidiary Odonto System to be settled until September 2024.

16.3. Other liabilities

These are amounts payable as a result of the acquisition of subsidiaries, some of which have already been merged into the Company.

	Company		Consolidated	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Papaiz Group	-	-	-	1,323
Odonto System ¹	11,807	13,648	11,807	13,648
Mogidonto	7,150	-	7,150	7,126
Boutique Dental	-	-	-	4,665
	18,957	13,648	18,957	26,762

¹Provision for potential risks of acquirees companies against other receivables (Note 9.3).

16.4. Investments payable

According to Odonto System's purchase agreement, to secure the obligation to indemnify the sellers, the Company maintains a portion of the investment payable: (i) Odonto System - within five years by disbursing 20% upon each anniversary of the contract; and (ii) Mogidonto – settlement in 6 equal installments on the anniversary date of the contract.

	Company		Consolidated	
	December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Opening balance	21,758	15,993	21,767	16,001
(+) Investment and PPA - Mogidonto ¹	-	7,541	-	7,541
(-) Payment - Odonto System	(291)	(1,781)	(292)	(1,781)
(+) Inflation adjustment	1,720	538	1,720	538
(-) Business combination - Mogidonto and Boutique	(1,158)	-	(1,158)	-
(-) Write-off of contingencies	(1,310)	(533)	(1,310)	(532)
	20,719	21,758	20,727	21,767
Current liabilities	15,968	8,637	15,968	8,637
Non-current liabilities	4,751	13,121	4,759	13,130
	20,719	21,758	20,727	21,767

¹Subsidiary merged as of January 03, 2022

17. Shareholders' equity

17.1. Capital

	Company	
	December 31, 2022	December 31, 2021
Subscribed and paid-up capital (in thousands of reais)	851,017	851,017
Number of common shares, without par value (number of shares)	568,465,803	531,294,792
Article 7 of Bylaws - authorization for the issuance of shares, without amendment to the Bylaws (number of shares)	80,000,000	80,000,000
Closing quotation: ODPV3 - B3 SA Brasil Bolsa Balcão (R\$/share)	9.03	12.60
Equity value (R\$/share)	1.29	2.18

17.2. Capital reserves

Options granted: due to the end of the validity period to exercise the options related to the granting of the stock option program, they were written off against "additional paid-in capital".

Additional paid-up capital: amount of the difference between the constitution estimated by the Black & Scholes methodology and the amount of the exercise from 1st to 12th grants of options. As of December 31, 2022, the Company

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

absorbed the balance recorded in “additional paid-in capital”, having as a contra entry the profit reserve group, “investment and expansion reserve”.

Other capital reserves: put option on subsidiaries and premium/discount on capital transaction.

17.3. Profit reserves

	Company and Consolidated	
	December 31, 2022	December 31, 2021
Legal reserve	73,921	51,313
Statutory Reserve of Regulatory ¹ Capital	174,568	243,147
Investment and expansion ¹ reserve	260,322	221,226
Tax incentive reserve	129	129
Additional dividend proposed	24,087	-
	533,027	515,815

¹On April 4, 2022, the Annual Meeting canceled 14,507,698 Treasury shares.

Legal reserve: mandatorily formed by the Company, upon destination of 5% of net income for the year, until its value achieves 20% of capital.

Statutory regulatory capital reserve: constituted by the Company, with the allocation of up to 50% of the net income of the year, whose purpose and objective is to meet the capital requirement regulation related to the solvency margin required by ANS, limited, together with the “Reserve for investment and expansion” to 80% of the capital.

Investment and expansion reserve: constituted by the Company, with the allocation of up to 50% of the net income for the year, whose purpose and objective is to finance the development, growth and expansion of the Company’s business, allowing the realization of new investments, including acquisitions of software and hardware, investments in facilities and equipment, acquisition of equity interests, business units and commercial establishments, limited, together with the “Statutory reserve of regulatory capital” to 80% of the capital.

Additional dividend proposed: corresponds to complementary dividends above the mandatory minimum (Notes 17.5 and 29).

17.4. Treasury shares

In 2021, the Company started Share Buyback Programs, approved by the Board of Directors, which, in addition to regular payments of interest on own capital, interim dividends and selective acquisitions in the dental value chain, demonstrate the objective of maximizing the generation of value for shareholders.

As of March 30, 2021, the Company started its first Buyback Program of up to 10 million shares, representing 3.80% of the 263,456,766 outstanding shares in the market, which was fully implemented until October 28, 2021, on the date a second Buyback Program was started, also up to 10 million shares, fully implemented until April 28, 2022. On the same date, a third Buyback Program was started, in the amount of up to 18 million shares, being effective until October 30, 2023.

On April 4, 2022, the Annual Meeting canceled 14,507,698 Treasury shares and authorized the split of one new share for every 10 existing shares, increasing the total capital from R\$ 531,294,792 to R\$ 568,465,803 shares.

As of December 31, 2022, the total number of shares held in Treasury reached 15,970,140 shares (14,507,698 shares as of December 31, 2021), of which 9,272,800 shares were acquired within the third Buyback Program in force, with an average cost of R\$ 9.67 per share.

As of December 31, 2022, the balance of treasury shares is R\$ 163,046 (R\$ 189,805 as of December 31, 2021).

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

17.5. Retained earnings, minimum and additional mandatory dividends

	Company	
	December 31, 2022	December 31, 2021
Net income for the year	452,171	380,359
Proposal for allocation of income:	(452,171)	(380,359)
Legal reserve	(22,608)	(19,018)
Interest on own capital	(69,257)	(52,232)
Interim dividends	(60,000)	(95,754)
Supplementary dividend to the minimum required	(95,913)	(40,520)
Additional dividend proposed	(24,087)	-
Investment and expansion reserve	(180,306)	(172,835)
	-	-

	Company	
	2022	December 31, 2021
Net income for the year	452,171	380,359
(-) Legal reserve	(22,608)	(19,018)
Adjusted calculation basis	429,563	361,341
(%) Minimum percentage of dividend according to Bylaws	50	50
Minimum compulsory dividend	214,781	180,671
Interim dividends	60,000	95,754
Interest on own capital ¹	58,868	44,397
Complementary dividend above the mandatory minimum	95,913	40,520
Additional dividend proposed	24,087	-
Dividends and interest on own capital authorized	238,868	180,671
Mandatory minimum dividend in excess	(24,087)	-
Minimum compulsory dividend	214,781	180,671

¹ Net of withholding income tax (IRRF) of 15%.

17.6. Resolutions

Approval	Type	Date	Resolution	Dividend per share (R\$)	Payment date	Company	
						2022	Competence 2021
RCA	Interest on own capital	03/11/2021		0.02447	04/06/2021	-	12,980
RCA	Interest on own capital	06/11/2021		0.02568	07/06/2021	-	13,500
RCA	Interest on own capital	09/13/2021		0.02589	10/06/2021	-	13,481
RCA	Interest on own capital	12/14/2021		0.02368	12/30/2021	-	12,271
RCA	Interest on own capital	03/21/2022		0.03192	07/06/2022	16,359	-
RCA	Interest on own capital	06/20/2022		0.03168	12/21/2022	17,633	-
RCA	Interest on own capital	09/15/2022		0.03169	12/27/2022	17,534	-
RCA	Interest on own capital	12/12/2022		0.03169	12/27/2022	17,731	-
				Interest on own capital		69,257	52,232
RCA	Dividends	04/28/2021		0.18101	07/06/2021	-	95,754
RCA	Dividends	04/27/2022		0.10720	10/05/2022	60,000	-
					Interim dividends	60,000	95,754
AUG	Additional dividend proposed	04/04/2022		0.07841	10/05/2022	-	40,520
AUG	Additional dividend proposed	03/01/2023		0.17359	12/07/2023 ¹	95,913	-
					Additional dividend to the minimum mandatory	95,913	40,520

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

AUG	Additional dividend proposed	03/01/2023	0.04359	12/07/2023 ¹	24,087	-
				Additional dividend	24,087	-
				Total deliberated earnings	249,257	188,506

RCA = Board of Directors' Meeting.

AGO = Ordinary General Meeting

If approved during the Ordinary General Meeting, it will be paid on July 12, 2023

18. Operating segments

The activities of the Company and its subsidiaries are organized in the following business segments:

- Corporate: includes clients over 200 beneficiaries;
- Small and Medium-sized enterprise (SME): clients sized between 3 and 199 beneficiaries;
- Individual: monthly and annual plans sold to individuals;
- Other: segments with less representation in the Company's total revenues, as follows: (i) dental care service in the Company's dental clinics (Clidec and Boutique Dental); (ii) management and advisory services provided (Odontoprev Serviços and Oprev); (iii) acquisition and distribution of dental care materials for the accredited network (Dental Partner); (iv) software development (Easy) and (v) health insurance (Odontored).

	Contribution margin per operating segment - Consolidated									
	CORPORATE		SME		INDIVIDUAL		OTHER		TOTAL	
	Year ended December 31, 2022	Year ended December 31, 2021	Year ended December 31, 2022	Year ended December 31, 2021	Year ended December 31, 2022	Year ended December 31, 2021	Year ended December 31, 2022	Year ended December 31, 2021	Year ended December 31, 2022	Year ended December 31, 2021
Net considerations/Retained premiums	1,109,321	1,070,084	402,871	351,886	455,305	476,625	-	-	1,967,497	1,898,595
Direct taxes from operations with health care plans for the operator	(41,014)	(40,771)	(21,891)	(18,077)	(27,928)	(23,979)	-	-	(90,833)	(82,827)
Sales of goods and services	-	-	-	-	-	-	21,892	16,406	21,892	16,406
Taxes on sales of goods and services	-	-	-	-	-	-	(14,813)	(14,247)	(14,813)	(14,247)
Insurance ²	-	-	-	-	-	-	18,679	24,507	18,679	24,507
SALES REVENUE	1,068,307	1,029,313	380,980	333,809	427,377	452,646	25,758	26,666	1,902,422	1,842,434
Cost of services ¹	(519,387)	(478,292)	(99,301)	(95,297)	(104,063)	(144,582)	(7,330)	(6,143)	(730,081)	(724,314)
OPERATING INCOME	548,920	551,021	281,679	238,512	323,314	308,064	18,428	20,523	1,172,341	1,118,120
Sales expenses	(75,533)	(64,642)	(48,949)	(42,478)	(87,107)	(83,459)	(503)	(517)	(212,092)	(191,096)
CONTRIBUTION MARGIN	473,387	486,379	232,730	196,034	236,207	224,605	17,925	20,006	960,249	927,024
Sales revenue (%)	56.2	55.9	20.0	18.1	22.5	24.6	1.4	1.4	100.0	100.0
Margin x sales revenue (%)	44.3	47.3	61.1	58.7	55.3	49.6	69.6	75.0	50.5	50.3
Distribution of margin x total/segment (%)	49.3	52.5	24.2	21.1	24.6	24.2	1.9	2.2	100.0	100.0

¹It excludes the provision for incurred events/claims but not reported (PEONA) and technical reserves for claims (note 21).

²Refers to insurance revenue from subsidiary Odontored.

19. Sales revenue

	Company		Consolidated	
	Year ended December 31,		Year ended December 31,	
	2022	2021	2022	2021
Net considerations/Retained premiums	1,967,571	1,891,478	1,967,497	1,898,595
Direct taxes from operations with health care plans for the operator	(90,833)	(82,448)	(90,833)	(82,827)
Effective considerations/earned premium from healthcare plans	1,876,738	1,809,030	1,876,664	1,815,768
Sale of goods and services	-	-	21,892	16,406
Insurance	-	-	18,679	24,507
Taxes on sales of goods and services	-	-	(14,813)	(14,247)
	1,876,738	1,809,030	1,902,422	1,842,434

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

20. Cost of Services

	Company		Consolidated	
	Year ended December 31,		Year ended December 31,	
	2022	2021	2022	2021
Known or reported events/claims	(687,436)	(695,884)	(675,268)	(688,291)
PEONA change	(2,342)	(6,948)	(2,342)	(6,921)
Net indemnifiable events/retained claims	(689,778)	(702,832)	(677,610)	(695,212)
Payroll charges on services	-	-	-	(98)
Dental materials	(12,466)	(14,253)	(6,349)	(8,805)
Other operating costs	(24,167)	(7,567)	(42,695)	(22,194)
Operational materials	(3,141)	(3,429)	(3,141)	(3,429)
Own units	-	-	(18,528)	(14,627)
(Provisions) reversals ¹	(21,026)	(4,138)	(21,026)	(4,138)
Sinistros ²	-	-	(5,769)	(4,926)
Claims - Technical reserves	-	-	(20)	(242)
	(726,411)	(724,652)	(732,443)	(731,477)

¹It includes provisions for individual plans with free choice of professionals through the banking channel (see note 15).

²Refers to claims arising from the subsidiary Odontored.

21. Marketing expenses (sales expenses)

Refer to commissions and agency paid to independent brokers and other distribution channels. As of December 31, 2022, they totaled R\$ 210,137 and R\$ 212,092 (R\$ 188,791 and R\$ 191,096 as of December 31, 2021) in the Company and Consolidated, respectively.

22. Administrative expenses (AE)

	Company		Consolidated	
	Year ended December 31,		Year ended December 31,	
	2022	2021	2022	2021
Personnel and outsourced services	(246,485)	(205,039)	(222,893)	(203,999)
Localization and operation	(29,679)	(22,800)	(35,019)	(27,681)
Advertising and publicity	(14,917)	(16,872)	(15,994)	(17,600)
Rates and taxes ¹	36,255	(9,655)	34,342	(10,609)
Depreciation and amortization	(29,781)	(55,433)	(32,395)	(57,760)
Other	(12,989)	(6,394)	(14,608)	(7,810)
Subtotal	(297,596)	(316,193)	(286,567)	(325,459)
Amortization of right-of-use (CPC 06 (R2)/IFRS 16)	(2,557)	(3,788)	(4,628)	(5,822)
Rentals	(2,467)	(4,675)	(5,596)	(7,213)
Rents (CPC 06(R2)/IFRS 16)	2,386	4,772	5,027	7,234
Income (loss) from disposal or write-off of non-current asset items and other	(6,482)	(1,106)	(6,642)	(1,124)
	(306,716)	(320,990)	(298,406)	(332,384)

¹It mainly refers to the refund of Private Health Insurance Regulatory Tax per healthcare plan (Note 16.1 a (i)).

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

23. Financial income (loss)

	Company		Consolidated	
	Year ended December 31,		Year ended December 31,	
	2022	2021	2022	2021
Yields from financial investments	74,049	49,856	77,197	51,015
Monetary restatement of National Social Security Institute - INSS Contribution - 5 previous years	-	168	-	168
Inflation adjustment on judicial deposits	279	135	304	146
Other	10,788	2,528	11,342	2,954
Financial revenues	85,116	52,687	88,843	54,283
Bank fees	(4,389)	(4,467)	(4,432)	(4,520)
Adjustment to present value (PVA) - lease liability (CPC 06 (R2)/IFRS 16)	(601)	(2,196)	(1,322)	(2,983)
Inflation adjustment of provisions for judicial contingencies ²	945	(1,757)	935	(1,769)
Inflation adjustment - INSS return	(1,123)	(416)	(1,123)	(416)
Inflation adjustment of investment payable ¹	-	(800)	-	(800)
Discounts granted	(1,136)	(1,680)	(1,137)	(1,869)
Other financial expenses	(8,324)	(1,843)	(9,097)	(2,700)
Financial expenses	(14,628)	(13,159)	(16,176)	(15,057)
	70,488	39,528	72,667	39,226

¹Refers to the update of the portion of the price withheld to guarantee the obligation to indemnify the former partners of Odonto System.

²See note 16.1.(a)(i)

24. Calculation of IRPJ/CSLL

	Company		Consolidated	
	Year ended December 31,		Year ended December 31,	
	2022	2021	2022	2021
IRPJ and CSLL calculation basis	636,587	543,399	646,258	547,178
(x) Current rate (%)	34	34	34	34
Estimate of IRPJ and CSLL expenses, according to the current rate	(216,440)	(184,756)	(219,728)	(186,041)
Effect of Corporate Income Tax and Social contribution on permanent/temporary differences:				
Equity in net income of subsidiaries	7,598	4,159	2,247	2,287
Provision for credit losses (Note 9.1)	334	2,077	329	2,081
Provision for lawsuits (Note 9.1)	10,510	(6,133)	10,579	(6,112)
Sundry provisions (Note 9.1)	769	4,775	917	4,552
Long-term incentive program (ILP) (Note 9.1)	(2,790)	(2,439)	(2,893)	(2,566)
Amortization of goodwill (Note 9.1)	12,097	10,990	12,097	10,990
Interest on own capital	23,547	17,759	23,547	17,759
Adjustments - Law 12973/14	(262)	(412)	(314)	(534)
Tax loss	-	-	(176)	61
Technological Innovation in 2021	3,858	2,311	3,858	2,311
PAT 2017	1,619	1,265	1,619	1,265
Other	(6,525)	(4,461)	(8,096)	(4,327)
IRPJ and CSLL expense	(165,685)	(154,865)	(176,014)	(158,274)
Deferred IRPJ and CSLL revenue (expense)	(18,731)	(8,175)	(18,883)	(7,564)
Total IRPJ and CSLL expense	(184,416)	(163,040)	(194,897)	(165,838)
Effective rate	-29.0%	-30.0%	-30.2%	-30.3%

25. Earnings per share

(a) Basic

	Year ended December 31,	
	2022	2021
Income attributable to Company's shareholders (in thousands of reais)	452,171	380,359
Weighted average number of common shares issued (thousands)	552,921	526,687
Basic earnings per share (R\$)	0.81779	0.72217

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

(b) Diluted

	Year ended December 31,	
	2022	2021
Income attributable to Company's shareholders (in thousands of reais)	452,171	380,359
Common shares (in thousands)		
Weighted average number of shares issued	552,921	526,687
Adjustment of stock options	-	652
Weighted average number of shares for the diluted earnings per share	552,921	527,339
Diluted earnings per share (R\$)	0.81779	0.72128

26. Right-of-use and lease liabilities – CPC 06 (R2) / IFRS 16

The Company and its subsidiaries recognized lease liabilities related to the rental of real estate properties in accordance with the assumptions in CPC 06 (R2)/IFRS 16 – Leases. These liabilities were measured considering the present value of future lease payments, discounted using the average rate of 6.99%, and the corresponding entry was recorded as right of use in assets. The total impacts measured are presented below:

	Rating	Company		Consolidated	
		December 31, 2022	December 31, 2021	December 31, 2022	December 31, 2021
Right to use	Non-current assets	15,344	41,959	26,330	56,986
Accumulated amortization	Non-current assets	(2,578)	(10,543)	(6,589)	(16,268)
Assets		12,766	31,416	19,741	40,718
Lease liabilities	Current liabilities	2,059	4,785	3,659	6,943
Adjustment to present value	Current liabilities	(979)	(2,218)	(1,333)	(2,872)
		1,080	2,567	2,326	4,071
Lease liabilities	Non-current liabilities	17,753	37,852	22,679	48,100
Adjustment to present value	Non-current liabilities	(3,743)	(7,451)	(4,584)	(9,406)
		14,010	30,401	18,095	38,694
Liabilities		15,090	32,968	20,421	42,765

27. Related parties

Related party transactions are carried out at values, terms and average rates in line with the ones practiced with third parties (if any), in force on the respective dates.

Company's Operations with its Subsidiaries and Associated Companies (Note 1)								
Assets/(Liabilities)	Type	Odontoprev	Clidec	Odontoprev Serviços	Easy	Dental Partner	Boutique Dental	Brasildental
Other credits receivable	Administrative services	4,203	-	619	-	139	-	-
Suppliers of assets and services	Administrative services	(139)	-	-	-	-	-	(4,822)
Revenue (Expense)								
Net payments	Dental care plans	74	-	-	-	-	-	-
Net payments	Assumed/transferred co-responsibility	14,390	-	-	-	-	-	(14,390)
Known or reported events/claims	Assumed/transferred co-responsibility	35,091	-	-	-	-	-	(35,091)
Other cost of services	Dental materials and services	-	(24)	-	-	-	-	-
Sales of goods and services	Administrative services	-	25,308	60,405	-	14,553	1,744	-
Known or reported events	Dental services	(12,168)	-	-	-	-	-	-
Other dental costs	Dental materials	(13,937)	(574)	-	-	-	(41)	-
Administrative expenses	Administrative services	(75,241)	-	10,009	(50)	-	-	(10,058)
December 31, 2022		(51,791)	24,710	70,414	(50)	14,553	1,703	(59,539)
December 31, 2021		(44,849)	20,002	67,037	(49)	14,827	-	(56,968)

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

The Company and its subsidiaries conduct transactions with companies of the Grupo Bradesco, of which Bradesco Saúde, shareholder of Odontoprev, is part:

Transactions	Companies related to Banco Bradesco	Nature	Consolidated	
			2022	December 31, 2021
Assets/(Liabilities)				
Cash and cash equivalents	Banco Bradesco S.A.	Current account	834	819
Interest earning bank deposits	Banco Bradesco S.A.	Interest earning bank deposit	771,562	700,068
Considerations receivable	Banco Bradesco S.A.	Considerations receivable	4,342	4,374
Considerations receivable	Bradesco Capitalização S.A.	Special savings bonds	1,047	2,019
Service providers	Bradesco Vida e Previdência S.A.	Life insurance - Employees	-	(26)
Service providers	Bradesco Cartões S.A.	Travel and accommodation - officers and employees	-	(140)
Revenue (Expense)				
Net consideration	Banco Bradesco S.A.	Sales revenue	51,948	54,807
Other operating revenues	Mediservice	Management fee	378	408
Other operating revenues	Stelo S.A.	Management fee	(70)	-
Sales expenses	Bradseg Promotora de Vendas S.A.	Commissions	(13,740)	(22,070)
Sales expenses	Banco Bradesco S.A.	Commissions	(3,366)	(6,068)
Sales expenses	Bradesco Corretora de Seguros Ltda.	Commissions	(59)	(68)
DA - Personnel and outsourced services	Banco Bradesco S.A.	Bookkeeping shares	(317)	(287)
DA - Personnel and outsourced services	Bradesco Saúde S.A.	Health care - Employees	(12,244)	(11,962)
DA - Personnel and outsourced services	Bradesco Vida e Previdência S.A.	Life insurance - Employees	(340)	(491)
DA - Personnel and outsourced services	Santecorp Holding Ltda	Medical/outpatient services	(279)	(427)
DA - Personnel and outsourced services	Alelo S.A.	Employee benefits	(4,353)	(7,568)
DA - Localization and operation	Banco Bradesco S.A.	Rents of branches	(282)	(112)
DA - Localization and operation	Brescia Empreendimentos E Participações Ltda.	Rents of branches	(21)	48
DA - Localization and operation	Bsp Empreendimento Imobiliário D166 Ltda.	Rents of branches	(80)	92
DA - Localization and operation	Reno Empreendimentos E Participações Ltda.	Rents of branches	(21)	21
DA - Other	Banco Bradesco S.A.	Travel and accommodation - officers and employees	(2,457)	(676)
DA - Other	Bsp Park Estacionamentos E Participações S.A.	Parking lot	(7)	(6)
DA - Other	Bradesco Auto Re Cia de Seguros	Civil Liability Insurance and insurance guarantee	(32)	(329)
DA - Other	Swiss Re Corporate Solutions Brasil Seguros S.A.	Legal guarantee insurance	(225)	(128)
DA - Other	Stelo S.A.	Financial services	(84)	(12)
Financial expenses	Banco Bradesco S.A.	Investment management	(323)	(322)
Financial expenses	Banco Bradesco S.A.	Bank fee	(2,822)	(2,697)
Financial revenues	Banco Bradesco S.A.	Revenue from interest earning bank deposits	76,921	50,436
Donations	Fundação Bradesco	Donations	-	(785)
Deliberated IOE	Bradesco Saúde S.A.	JCP	(35,599)	(26. 1-21)
			52,526	25,683

As mentioned in Note 16.1 (d), the Company contracted a court guarantee insurance related to the tax assessment notices on the stock options whose policies were contracted together with Swiss Re Corporate Solutions Brasil Seguros S.A. (Swiss Re Brasil) which has a joint venture with Bradesco Seguros S.A. (Bradesco Seguros).

The Company and its subsidiaries grant profit sharing to its employees and officers linked to the achievement of operating goals and specific objectives established and approved at the beginning of each year. As at December 31, 2022, the amounts of R\$ 23,605 (R\$ 20,037 as of December 31, 2021) and R\$ 26,106 (R\$ 24,082 as of December 31, 2021) were appropriated as profit sharing in the Company and in the Consolidated.

In 2019, the Company implemented a long-term incitement program (ILP Program), which establishes the criteria for the payment of cash bonuses, corresponding to salary multiples, to be made by the Company and its subsidiaries to the eligible beneficiaries after the measurement period, provided that the goals and conditions established in the terms are met. The stock options program remains in effect, as approved by the Shareholders' Meeting with the last granting being made in 2016.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

The measurement period corresponds to three years and the payment is conditioned upon the achievement of the corporate performance targets established by the Board of Directors and the service condition.

As of December 31, 2022, the amounts of R\$ 20,081 and R\$ 21,077 in the Company and Consolidated, respectively (R\$ 16,067 and R\$ 17,384 as of December 31, 2021) were appropriated to income (loss) for the period.

The annual fixed remuneration attributed to the Board of Directors and the Tax Council and the fixed/variable remuneration attributed to the Statutory Executive Board were as follows:

	Year ended December 31,	
	2022	2021
Statutory Board	21,369	19,023
Directors' fee	6,057	5,572
Benefits	657	596
Bonus	7,295	6,736
ILP	7,360	6,119
Board of Directors	3,155	2,767
Directors' fee	3,155	2,767
Tax Council	503	469
Directors' fee	503	469
	25,027	22,259

The Board of Directors and Tax Council, as well the Audit Committee and the Personnel Management Committee, include members of the Bradesco Group.

The Company does not sponsor a supplementary pension plan or any other post-employment benefit or termination of employment contract.

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

28. Cash flow – Direct method

	Company	
	Year ended December 31,	
	2022	2021
OPERATING ACTIVITIES		
Health Plan income	1,984,463	1,846,299
Redemption of interest earning bank deposits (Note 6)	1,281,685	1,291,492
Interest receipt of interest earning bank deposits (Note 6)	78,286	49,856
Other operating income	7,844	35,616
Payments to suppliers/health service providers (Note 14.2)	(674,208)	(712,093)
Payment of commissions	(190,733)	(190,010)
Payment of personnel	(94,722)	(75,419)
Payment of Directors' fees	(12,971)	(11,237)
Payments of outsourced services	(131,954)	(99,920)
Payments of taxes	(282,985)	(242,700)
Payments of lawsuits (civil/labor/tax)	(27,131)	(11,892)
Payment of rent	(3,594)	(6,436)
Payment of promotion/advertising	(15,385)	(17,234)
Interest earning bank deposits (Note 6)	(1,419,598)	(1,331,332)
Other operating payments	(35,078)	(36,487)
CASH GENERATED BY OPERATING ACTIVITIES	463,919	488,503
INVESTMENT ACTIVITIES		
Receipts of dividends	5,169	5,526
Payment for the acquisition of property, plant and equipment (Note 12)	(6,799)	(5,055)
Payments for acquisition of interest in other companies	(44,394)	(15,730)
Other payments from investment activities	(62,637)	(46,031)
CASH INVESTED IN INVESTMENT ACTIVITIES	(108,661)	(61,290)
FINANCING ACTIVITIES		
Other receipts from investment activities (DMPL)	52	1,188
Payments of profit sharing	(16,212)	(15,099)
Other payments from financing activities	(339,867)	(431,164)
CASH INVESTED IN FINANCING ACTIVITIES	(356,027)	(445,075)
(DECREASE) IN CASH AND CASH EQUIVALENTS	(769)	(17,862)
NET CHANGES IN CASH		
Opening balance	15,584	33,446
Closing balance	14,815	15,584
(DECREASE) IN CASH AND CASH EQUIVALENTS	(769)	(17,862)
Non-restricted assets at the beginning of the period	525,104	557,209
Non-restricted assets at the end of the period	492,680	525,104
(DECREASE) IN INTEREST EARNING BANK DEPOSITS - FREE FUNDS	(32,424)	(32,105)
CASH GENERATED BY OPERATING ACTIVITIES (direct method)	463,919	488,503
(+/-) Amounts classified differently between the methods		
Interest earning bank deposits measured at amortized cost	244,315	382,946
Profit sharing	(16,212)	(15,099)
Write-off of investments due to merger	(4,483)	(4,470)
CASH GENERATED BY OPERATING ACTIVITIES (indirect method)	687,539	851,880

Odontoprev S.A.

Notes to the financial statements (Company and Consolidated)

December 31, 2022 and 2021

(Amounts expressed in thousands of Reais, unless otherwise indicated)

29. Subsequent events

(i) Acquisition of control of “Papaiz” common shares.

According to the Notice to the Market published on February 1, 2023, the acquisition of control of common shares representing 51% of the capital of Papaiz Associados Diagnósticos por Imagem S.A. (“Papaiz”) through its subsidiary Clidec Participações S.A. was completed after the Administrative Council for Economic Defense (“CADE”) approved, without any restriction, the consummation of said transaction.

The transaction does not represent a material investment for Odontoprev and will not be subject to shareholders’ approval.

(ii) CVM/SNC/SEP CIRCULAR LETTER 1/2023

The Company and its subsidiaries inform that they do not have a tax proceeding (either active or closed) with the purpose of judging topics 881 and 885 (general repercussion) of the Federal Supreme Court (STF) of February 8, 2023. It also informs that they are assessing, together with their legal advisors, the impacts of understanding said decision on their administrative and judicial tax proceedings, either closed and in progress, which has not revealed any relevant impacts on their financial statements for the year ended December 31, 2022.

Other information the Company deems to be relevant

SHAREHOLDING POSITION OF THE HOLDERS OF OVER 5% OF THE COMPANY'S SHARES						
Position as of 12/31/2022						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradesco Saúde S/A	292,213,236	51.40	-	-	292,213,236	51.40
1832 Asset Management L.P.	29,341,032	5.16	-	-	29,341,032	5.02
Treasury shares	15,970,140	2.81	-	-	15,970,140	2.81
Outstanding shares	230,941,395	40.63	-	-	230,941,395	40.63
Total	568,465,803	100.00	-	-	568,465,803	99.86

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradesco Saúde S/A						
Position as of 12/31/2022						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradesco Gestão de Saúde S.A.	20,870,945	100.00	-	-	20,870,945	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradesco Gestão de Saúde						
Position as of 12/31/2022						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Bradseg Participações S.A.	12,251,025,598	100.00	-	-	12,251,025,598	100.00
Bradesco SegPrev Investimentos Ltda	-	-	-	-	-	-
Total	12,251,025,598	100.00	-	-	12,251,025,598	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Bradseg Participações S.A.						
Position as of 12/31/2022						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Banco Bradesco S.A.	12,317	100.00	-	-	12,317	100.00
Total	12,317	100.00	-	-	12,317	100.00

*according to the Reference Form of 01/16/2023, available on the RI website of Banco Bradesco.

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Banco Bradesco S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Cidade de Deus Companhia Comercial de Participações	2,445,219,983	45.80	1,292,135	0.02	2,446,512,118	22.95
Fundação Bradesco	914,471,663	17.13	-	-	914,471,663	8.58
NCF Participações S.A.	451,890,822	8.46	119,774,968	2.25	571,665,790	5.36
Other	1,518,722,243	28.45	5,190,798,444	97.57	6,709,520,687	62.95
Treasury shares	8,089,200	0.15	8,228,600	0.15	16,317,800	0.15
Total	5,338,393,911	100.00	5,320,094,147	100.00	10,658,488,058	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Cidade de Deus Companhia Comercial de Participações						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Fundação Bradesco	2,779,096,922	35.44	-	-	2,779,096,922	35.44
Nova Cidade de Deus Participações S.A.	3,758,724,093	47.93	-	-	3,758,724,093	47.93
Other	1,304,138,509	16.63	-	-	1,304,138,509	16.63
Total	7,841,959,524	100.00	-	-	7,841,959,524	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: NCF Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Cidade de Deus Companhia Comercial de Participações	1,259,587,222	74.72	-	-	1,259,587,222	39.51
Fundação Bradesco	423,598,233	25.13	1,502,370,308	100.00	1,925,968,541	60.41
Nova Cidade de Deus Participações S.A.	2,521,897	0.15	-	-	2,521,897	0.08
Total	1,685,707,352	100.00	1,502,370,308	100.00	3,188,077,660	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Fundação Bradesco						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Other	1	100.00	-	-	1	100.00
Total	1	100.00	-	-	1	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: Nova Cidade de Deus Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
BBD Participações S.A.	189,425,112	53.70	-	-	189,425,112	26.07
Fundação Bradesco	163,332,621	46.30	373,794,914	100.00	537,127,535	73.93
Total	352,757,733	100.00	373,794,914	100.00	726,552,647	100.00

BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: BBD Participações S.A.						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Treasury shares	47,364,860	30.63	23,831,923	15.43	71,196,783	23.03
NCD Participações Ltda	-	-	74,784,306	48.42	74,784,306	24.19
Other	107,283,917	69.37	55,829,904	36.15	163,113,821	52.77
Total	154,648,777	100.00	154,446,133	100.00	309,094,910	100.00


BREAKDOWN OF CAPITAL OF LEGAL ENTITIES (COMPANY'S SHAREHOLDERS), DOWN TO INDIVIDUAL						
Name: NCD Participações Ltda						
Shareholder	Common shares		Preferred shares		Total	
	Quantity	%	Quantity	%	Quantity	%
Fundação Bradesco	793,303,109	99.99	-	-	793,303,109	99.99
Other	1	0.01	-	-	1	0.01
Total	793,303,110	100.00	-	-	773,303,110	100.00

Other information the Company deems to be relevant

CONSOLIDATED SHAREHOLDING POSITION OF THE CONTROLLING SHAREHOLDERS AND DIRECTORS AND OFFICERS AND SHARES IN CIRCULATION						
Position as of 12/31/2022						
Shareholder	Number of common shares (in units)	%	Number of preferred shares (in units)	%	Total number of Shares (in units)	%
Controlling managers	292,213,236	51.40	-	-	292,213,236	51.40
Managers	1,376,495	0.24	-	-	1,376,495	0.24
Treasury shares	15,970,140	2.81	-	-	15,970,140	2.81
Other	258,905,932	45.54	-	-	258,905,932	45.54
Total	568,465,803	100.00	-	-	568,465,803	100.00
Outstanding shares	258,905,932	45.54	-	-	258,905,932	45.54

CONSOLIDATED SHAREHOLDING POSITION OF THE CONTROLLING SHAREHOLDERS AND DIRECTORS AND OFFICERS AND SHARES IN CIRCULATION						
Position as of 12/31/2021						
Shareholder	Number of common shares (in units)	%	Number of preferred shares (in units)	%	Total number of Shares (in units)	%
Controlling managers	265,648,397	50.01	-	-	265,648,397	50.01
Managers	1,253,088	0.24	-	-	1,253,088	0.24
Treasury shares	14,507,698	2.73	-	-	14,507,698	2.73
Other	249,885,609	47.02	-	-	249,885,609	47.02
Total	531,294,792	100.00	-	-	531,294,792	100.00
Outstanding shares	249,885,609	47.02	-	-	249,885,609	47.02

Other information the Company deems to be relevant





Independent Auditor's Report on the Individual and Consolidated Financial Statements

To the Management Board and Shareholders of
Odontoprev S.A.
Barueri - SP

Opinion

We have audited the individual and consolidated financial statements of Odontoprev S.A. ("the Company"), respectively referred to as Individual and Consolidated, which comprise the statement of financial position as at December 31, 2022, and the statements of profit or loss, other comprehensive income, changes in equity and cash flows for the year then ended, and notes, comprising significant accounting policies and other explanatory information.

Opinion on the individual financial statements

In our opinion, the accompanying individual financial statements present fairly, in all material respects, the financial position of the Odontoprev S.A. as at December 31, 2022, and of its financial performance and its cash flows for the year then ended in accordance with Accounting Practices Adopted in Brazil.

Opinion on the consolidated financial statements

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Odontoprev S.A. as at December 31, 2022, and of its consolidated financial performance and its cash flows for the year then ended in accordance with Accounting Practices Adopted in Brazil and with International Financial Reporting Standards (IFRS), issued by the International Accounting Standards Board (IASB).

Basis for Opinion

We conducted our audit in accordance with Brazilian and International Standards on Auditing. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Individual and Consolidated Financial Statements section of our report. We are independent of the Company and its subsidiaries in accordance with the relevant ethical requirements included in the Accountant Professional Code of Ethics ("Código de Ética Profissional do Contador") and in the professional standards issued by the Brazilian Federal Accounting Council ("Conselho Federal de Contabilidade") and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the individual and consolidated financial statements of the current period. These matters were addressed in the context of our audit of the individual and consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Measurement of technical provisions for dental care insurance

The Company maintains technical provisions related to dental care insurance contracts, as per explanatory notes 2.7, 2.8 and 13.2. To carry out the liability adequacy test and to measure the technical provision for events that occurred and not reported (PEONA), the Company uses actuarial techniques and methods that require judgment in determining methodologies and definition of assumptions that include the expectation of claims and discount rate. Additionally, as of 2023, come in force CPC 50/IFRS 17 – Insurance Contracts, which changes the criteria for recognition, measurement, presentation and disclosure of insurance contracts. In accordance with CPC 23/IAS 8 – Accounting policies, changes in estimates and correction of errors, the Company made disclosures in explanatory note 2.20, qualitative and quantitative, related to the most relevant impacts of the new pronouncement based on the balances of January 1, 2023. We consider the performance of the liability adequacy test, the measurement of the PEONA and assessing the impacts on the transition to CPC 50/IFRS 17 as a key audit matter, given that the assumptions used are subjective, and small variations in these assumptions can result in significant changes in the result of the adequacy test and in the measurement of these liabilities in the individual and consolidated financial statements.

How the matter was addressed in our audit

The main procedures we performed to address the matter that was significant to our audit included:

- (i) evaluation of the design of key controls related to the process of carrying out the liability adequacy test and measuring the PEONA, including controls related to the development and approval of actuarial methodologies and related assumptions, discount rate and claims expectation, as well as the review and approval of the calculations;

(ii) involvement of our actuarial specialists with knowledge and experience in the sector who helped us:

- in evaluating the assumptions used in carrying out the liability adequacy test and in measuring the PEONA, by establishing a best estimate range based on independent assumptions or those derived from the Company's own historical information;

- in determining an independent estimate of (PEONA), including the use of independent assumptions and generally accepted actuarial techniques;

- in the evaluation of the projections of claims made by the Company by comparing the historical estimates with the amounts actually observed;

(iii) the assessment of whether the disclosures in the financial statements regarding technical provisions, liability adequacy test and main quantitative and qualitative aspects of the transition to CPC 50/IFRS 17 consider the relevant information.

Based on the evidence obtained through the procedures summarized above, we consider the measurement of technical provisions for dental care insurance acceptable, in the context of the financial statements taken as a whole for the year ended December 31, 2022.

Evaluation of the recoverable amount of goodwill based on expected future profitability

As mentioned in notes 2.5 (e) (i) and 12.1, the Company has goodwill arising from the acquisition of investments. The Company performs impairment tests, at least annually or when there are events or circumstances that indicate that the carrying amount may not be recoverable. As part of the impairment test of these assets, the Company estimated the recoverable values of the Cash Generating Units "CGU" based on the present value of future cash flows, the realization of which is based on projections of future results based on business plans and budget prepared by the Company in relation to the CGUs and also based on historical data, which are supported by various economic and business assumptions.

We consider this matter a key audit matter due to the degree of judgment inherent in the determination of these estimates and the potential impact that any changes in significant

assumptions, which include the perpetuity growth rate, discount rate and macroeconomic assumptions, could have on the individual and consolidated financial statements.

How the matter was addressed in our audit

The main procedures we performed to address the matter that was significant to our audit included:

- (i) understanding the design of key controls related to the process of preparation, review and approval of the assumptions used in the evaluation of the recoverability studies prepared by the Company;
- (ii) involvement of our corporate finance professionals with knowledge and experience in the sector who helped to:
 - evaluation of the assumptions used, such as perpetuity growth rate, discount rate and macroeconomic assumptions, comparing them with information obtained from internal and external sources;
 - assessment of the discount rate used in the impairment test, comparing them to discount rate ranges that have been developed independently using publicly available market data for comparable entities;
 - assessment of the mathematical accuracy of present value calculations; and

(iii) assessment whether the disclosures in the financial statements consider the relevant information.

Based on the evidence obtained through the procedures summarized above, we consider it acceptable to assess the recoverable amount of goodwill based on expected future profitability, in the context of the financial statements taken as a whole for the year ended December 31, 2022.

Other matters

Statements of added value

The individual and consolidated statements of added value (DVA) for the year ended December 31, 2022, prepared under the responsibility of the Company's management, and presented herein as supplementary information for IFRS purposes, have been subject to audit procedures jointly performed with the audit of the financial statements of the Company. In order to form our opinion, we assessed whether those statements are reconciled with the financial statements and accounting records, as applicable, and whether their format and contents are in accordance with criteria determined in the Technical Pronouncement 09 (CPC 09) - Statement of Added Value. In our opinion, the statements of added value have been fairly prepared, in all material respects, in accordance with the criteria determined by the aforementioned Technical Pronouncement, and are consistent with the overall individual and consolidated financial statements.

Other information accompanying the individual and consolidated financial statements and the auditor's report

Management is responsible for the other information comprising the management report.

Our opinion on the individual and consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the individual and consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report on this regard.

Responsibilities of Management and Those Charged with Governance for the Individual and Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the individual and consolidated financial statements in accordance with Accounting Practices Adopted in Brazil and with International Financial Reporting Standards (IFRS), issued by the International Accounting Standards Board (IASB) and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the individual and consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company and subsidiaries or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's and subsidiaries financial reporting process.

Auditors' Responsibilities for the Audit of the Individual and Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the individual and consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Brazilian and international standards on auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Brazilian and international standards on auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the individual and consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's and its subsidiaries internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's and its subsidiaries ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the individual and consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company and subsidiaries to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the individual and consolidated financial statements represent the

underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

São Paulo, March 1st, 2023

KPMG Auditores Independentes Ltda.

CRC 2SP-028567/O-0 F SP

Original report in Portuguese was signed by

Cláudio Rogélio Sertório

Accountant CRC 1SP212059/O-0

Opinions and Statements / Tax Council opinion or equivalent body

The Tax Council of Odontoprev S.A., in compliance with legal and statutory provisions, examined the Management Report and the Financial Statements of the Company for the fiscal year ended December 31, 2022, as well as the Proposal for allocation of income for the year. Based on the examinations carried out and considering the Independent Auditors' Report on the Financial Statements, presented without qualifications, issued by KPMG Auditores Independentes Ltda. on March 01, 2023, believes that the aforementioned documents are in a position to be appreciated and voted on by the General Meeting.

Barueri/SP, March 01, 2023

Opinions and Statements / Summarized Report from Audit Committee (statutory, provided for in specific CVM regulation)

The members of the Audit Committee of Odontoprev S.A., in the exercise of its legal duties and responsibilities, as provided for in the article 27 of Company's Bylaws and Internal Rules, carried out the examination and analysis of the financial statements, together with the independent auditors' report and the Annual Management Report for the fiscal year ended December 31, 2022, as well as the proposal for allocation of income for the year and, considering information provided by Company's management and by KPMG Auditores Independentes Ltda., unanimously declare that they reflect fairly, in all material respects, the financial position of the Company, and recommend the approval of the documents by the Company's Board of Directors and its submission to the Annual General Meeting, pursuant to the terms of Law 6404/76.

Barueri/SP, March 01, 2023

Opinions and Statements / Statement of the Executive Officers on the Financial Statements

We declare, in our capacity as Statutory Directors of Odontoprev S.A., a joint stock company headquartered in the city of Barueri, state of São Paulo, at Alameda Araguaia, 2104, 21º Andar - Alphaville, CNPJ [EIN] 58.119.199/0001-51, pursuant to item VI, §1, article 27, CVM Instruction 80 of March 29, 2022, which we reviewed, discussed and agreed with the financial statements for the fiscal year ended December 31, 2022.

Barueri/SP, March 01, 2023

Opinions and Statements / Statement of the Executive Officers on Independent Auditor's Report

We declare, in our capacity as Statutory Directors of Odontoprev S.A., a joint stock company headquartered in the city of Barueri, state of São Paulo, at Alameda Araguaia, 2104, 21º Andar - Alphaville, CNPJ [EIN] 58.119.199/0001-51, pursuant to item VI, §1, article 27, CVM Instruction 80 of March 29, 2022, which we reviewed, discussed and agreed with the with the opinions expressed in the independent auditors' report of the Company, KPMG Auditores Independentes Ltda. regarding the financial statements for the fiscal year ended December 31, 2022.

Barueri/SP, March 01, 2023